[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 170
1. Cuschieri K, Wentzensen N: Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia. Cancer Epidemiol Biomarkers Prev; 2008 Oct;17(10):2536-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus mRNA and p16 detection as biomarkers for the improved diagnosis of cervical neoplasia.
  • Human papillomavirus (HPV) infection of the genital tract is very common and normally follows a benign clinical course; however, in an unfortunate minority of infected individuals, it can cause disease that sometimes leads to cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasm Proteins / genetics. Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. RNA, Messenger / analysis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Mass Screening / methods. Precancerous Conditions / diagnosis. Precancerous Conditions / genetics. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2006 Nov 1;107(9):2307-13 [17029280.001]
  • [Cites] Int J Cancer. 2007 Jan 15;120(2):351-6 [17066437.001]
  • [Cites] Cancer. 2006 Dec 25;108(6):494-500 [17063495.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):58-66 [17186505.001]
  • [Cites] Cancer. 2007 Feb 25;111(1):1-14 [17219448.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2435-8 [17294450.001]
  • [Cites] J Low Genit Tract Dis. 2007 Apr;11(2):98-104 [17415114.001]
  • [Cites] Cancer. 2007 Apr 25;111(2):83-92 [17334990.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1419-24 [17342094.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2599-605 [17473189.001]
  • [Cites] Int J Gynecol Pathol. 2007 Jul;26(3):223-8 [17581402.001]
  • [Cites] Dis Markers. 2007;23(4):213-27 [17627057.001]
  • [Cites] J Med Virol. 2000 Oct;62(2):251-8 [11002256.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Mol Diagn. 2001 Jun;6(2):125-30 [11468697.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7888-98 [11753671.001]
  • [Cites] Acta Cytol. 2002 Jan-Feb;46(1):25-9 [11843554.001]
  • [Cites] Ophthalmology. 2002 Mar;109(3):542-7 [11874759.001]
  • [Cites] J Mol Diagn. 2002 May;4(2):97-102 [11986400.001]
  • [Cites] Cancer. 2002 Apr 15;94(8):2199-210 [12001118.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1948-52 [16103442.001]
  • [Cites] Gynecol Oncol. 2005 Apr;97(1):35-40 [15790434.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):578-84 [16139346.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):461-7 [16116604.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1254-60 [16161049.001]
  • [Cites] Dis Markers. 2007;23(4):273-81 [17627062.001]
  • [Cites] Dis Markers. 2007;23(4):315-30 [17627065.001]
  • [Cites] Int J Cancer. 2004 Mar 1;108(6):871-6 [14712490.001]
  • [Cites] Lancet. 2007 Sep 8;370(9590):890-907 [17826171.001]
  • [Cites] N Engl J Med. 2007 Oct 18;357(16):1579-88 [17942871.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2787-93 [17722112.001]
  • [Cites] Lancet. 2007 Nov 24;370(9601):1764-72 [17919718.001]
  • [Cites] J Clin Pathol. 2008 Jan;61(1):132-7 [17468293.001]
  • [Cites] J Natl Compr Canc Netw. 2008 Jan;6(1):83-95 [18267061.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):502-12 [18223479.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1389-99 [12409715.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):365-70 [12451568.001]
  • [Cites] J Clin Pathol. 2003 Jan;56(1):56-63 [12499437.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Anal Quant Cytol Histol. 2003 Feb;25(1):8-11 [12630076.001]
  • [Cites] Cancer. 2003 Apr 25;99(2):89-96 [12704688.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):665-73 [12861062.001]
  • [Cites] EMBO J. 2003 Aug 15;22(16):4212-22 [12912919.001]
  • [Cites] Acta Cytol. 2003 Jul-Aug;47(4):616-23 [12920756.001]
  • [Cites] Gynecol Oncol. 2003 Oct;91(1):201-8 [14529682.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):492-6 [15006929.001]
  • [Cites] J Med Virol. 2004 May;73(1):65-70 [15042650.001]
  • [Cites] Acta Cytol. 2004 Mar-Apr;48(2):173-80 [15098536.001]
  • [Cites] Cancer. 2004 Apr 25;102(2):100-8 [15098254.001]
  • [Cites] Cancer. 2004 Jun 25;102(3):142-9 [15211472.001]
  • [Cites] J Clin Microbiol. 2004 Jul;42(7):3176-84 [15243079.001]
  • [Cites] J Med Virol. 2004 Sep;74(1):107-16 [15258976.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Aug;13(8):1355-60 [15298958.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):235-42 [15452898.001]
  • [Cites] Hum Pathol. 1992 Feb;23(2):117-28 [1310950.001]
  • [Cites] J Virol Methods. 1991 Dec;35(3):305-13 [1667790.001]
  • [Cites] Int J Cancer. 1992 Jul 9;51(5):831-4 [1319412.001]
  • [Cites] Gynecol Oncol. 1995 Feb;56(2):239-44 [7896192.001]
  • [Cites] J Virol Methods. 1995 Jul;54(1):75-81 [7559859.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4350-4 [8633069.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1741-8 [9846965.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):610-5 [15378361.001]
  • [Cites] Virchows Arch. 2004 Dec;445(6):616-20 [15480761.001]
  • [Cites] Acta Cytol. 2004 Nov-Dec;48(6):771-82 [15581161.001]
  • [Cites] Diagn Cytopathol. 2005 Jan;32(1):21-4 [15584047.001]
  • [Cites] J Virol Methods. 2005 Mar;124(1-2):211-5 [15664071.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):267-73 [15492761.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):367-72 [15734959.001]
  • [Cites] Int J Cancer. 2005 May 10;114(6):973-6 [15645423.001]
  • [Cites] J Clin Pathol. 2005 May;58(5):525-34 [15858126.001]
  • [Cites] Zentralbl Gynakol. 2005 Jun;127(3):140-5 [15915391.001]
  • [Cites] Gynecol Oncol. 2005 Jun;97(3):908-15 [15943992.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1072-9 [16030305.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):347-53 [16445657.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):791-6 [16287075.001]
  • [Cites] Mod Pathol. 2006 Mar;19(3):384-91 [16415792.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):525-41 [16597322.001]
  • [Cites] J Clin Microbiol. 2006 Apr;44(4):1310-7 [16597856.001]
  • [Cites] Cancer. 2006 Apr 25;108(2):119-23 [16411180.001]
  • [Cites] Int J Cancer. 2006 Sep 1;119(5):1102-7 [16570279.001]
  • [Cites] Br J Dermatol. 2006 Jul;155(1):129-36 [16792764.001]
  • [Cites] J Clin Pathol. 2006 Aug;59(8):827-30 [16467166.001]
  • [Cites] J Virol Methods. 2006 Oct;137(1):58-62 [16828171.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):62-6 [16494930.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):18-20 [16919709.001]
  • [Cites] J Clin Pathol. 2006 Oct;59(10):1017-28 [16679355.001]
  • (PMID = 18842994.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010124-14
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / RNA, Messenger
  • [Number-of-references] 89
  • [Other-IDs] NLM/ NIHMS212843; NLM/ PMC2900792
  •  go-up   go-down



2. Hsu A, Bray TM, Helferich WG, Doerge DR, Ho E: Differential effects of whole soy extract and soy isoflavones on apoptosis in prostate cancer cells. Exp Biol Med (Maywood); 2010 Jan;235(1):90-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign prostate hyperplasia (BPH-1), LnCap and PC3 cells were treated with varying concentrations of soy extract, genistein or daidzein and analyzed for cell cycle alterations and induction of apoptosis.
  • No significant changes in cell cycle arrest or apoptosis were observed in non-cancerous BPH-1 cells treated with soy extract, suggesting that the effects of soy extract may be tumor cell specific.
  • [MeSH-minor] Anticarcinogenic Agents / pharmacology. Caspases / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Dietary Supplements. Enzyme Activation / drug effects. Humans. Male. NF-kappa B / metabolism. Phytoestrogens / pharmacology. Plant Extracts / pharmacology. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 2003;21(5):744-57 [14628433.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1328-31 [8443813.001]
  • [Cites] Lancet. 1993 Nov 13;342(8881):1209-10 [7901532.001]
  • [Cites] Mutagenesis. 1994 Mar;9(2):101-6 [8201941.001]
  • [Cites] Carcinogenesis. 1996 Jul;17(7):1451-7 [8706248.001]
  • [Cites] Proc Soc Exp Biol Med. 1998 Mar;217(3):310-6 [9492340.001]
  • [Cites] J Cell Biochem. 1998 Apr 1;69(1):44-54 [9513045.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1055-65 [9829717.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5315-20 [9850056.001]
  • [Cites] J Urol. 1999 Jan;161(1):152-5 [10037388.001]
  • [Cites] Nutr Cancer. 1999;33(2):125-31 [10368806.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3486S-3492S [15570058.001]
  • [Cites] J Nutr. 2005 Jun;135(6):1400-6 [15930444.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):667-9 [15945102.001]
  • [Cites] J Agric Food Chem. 2005 Nov 2;53(22):8542-50 [16248551.001]
  • [Cites] BJU Int. 2005 Dec;96 Suppl 2:30-4 [16359436.001]
  • [Cites] J Nutr. 2006 Jan;136(1):75-82 [16365062.001]
  • [Cites] Prostate. 2006 Apr 1;66(5):557-66 [16372328.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):538-45 [17337648.001]
  • [Cites] J Nutr. 2007 Apr;137(4):964-72 [17374662.001]
  • [Cites] Biochim Biophys Acta. 2007 Jun;1773(6):903-11 [17490757.001]
  • [Cites] Nutr Cancer. 2007;57(2):184-93 [17571952.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2008;11(1):6-12 [17923857.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Oncol Rep. 2008 Apr;19(4):1061-6 [18357397.001]
  • [Cites] Oncogene. 2008 Oct 20;27(48):6252-75 [18931692.001]
  • [Cites] J Steroid Biochem Mol Biol. 1993 Feb;44(2):147-53 [8382517.001]
  • [Cites] Nutr Cancer. 1999;35(2):167-74 [10693171.001]
  • [Cites] Jpn J Cancer Res. 2000 Feb;91(2):164-73 [10761703.001]
  • [Cites] Am J Clin Nutr. 2000 Jun;71(6 Suppl):1705S-7S; discussion 1708S-9S [10837323.001]
  • [Cites] Prostate. 2001 May 15;47(3):183-8 [11351347.001]
  • [Cites] Oncogene. 2001 Jul 12;20(31):4188-97 [11464285.001]
  • [Cites] J Nutr. 2001 Nov;131(11 Suppl):3095S-108S [11694655.001]
  • [Cites] Prostate. 2002 May 1;51(2):133-40 [11948968.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2369-77 [12114442.001]
  • [Cites] J Nutr. 2002 Oct;132(10):3168-71 [12368413.001]
  • [Cites] Oncogene. 2003 Jul 24;22(30):4702-9 [12879015.001]
  • [Cites] Toxicol Lett. 2004 Apr 15;150(1):43-56 [15068824.001]
  • [Cites] Curr Med Chem Anticancer Agents. 2004 May;4(3):263-72 [15134504.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1649-57 [15131010.001]
  • [Cites] Urology. 2004 Sep;64(3):510-5 [15351581.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:225-61 [15377220.001]
  • [Cites] Int J Oncol. 2004 Nov;25(5):1389-95 [15492830.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Br J Nutr. 2004 Apr;91(4):513-31 [15035679.001]
  • (PMID = 20404023.001).
  • [ISSN] 1535-3699
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES00210; United States / NCI NIH HHS / CA / CA107693; United States / NCI NIH HHS / CA / R01 CA107693; United States / NIA NIH HHS / AG / P01 AG024387; United States / NIA NIH HHS / AG / P01-AG024387; United States / NCCIH NIH HHS / AT / P50 AT006268; United States / NIEHS NIH HHS / ES / P30 ES000210
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / BAX protein, human; 0 / Isoflavones; 0 / NF-kappa B; 0 / Phytoestrogens; 0 / Plant Extracts; 0 / bcl-2-Associated X Protein; 1POG3SCN5T / genistin; 6287WC5J2L / daidzein; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ NIHMS617415; NLM/ PMC4125131
  •  go-up   go-down



3. Wietfeldt ED, Thiele J: Malignancies of the anal margin and perianal skin. Clin Colon Rectal Surg; 2009 May;22(2):127-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignancies of the anal margin and perianal skin.
  • Malignancies of the anal margin and perianal skin are relatively uncommon lesions, comprising 3 to 4% of all anorectal malignancies.
  • Buschke-Lowenstein tumor, or giant condyloma acuminatum, is not always included because this lesion is technically benign, although it displays aggressive local invasive behavior that makes it difficult to manage.
  • Proper diagnosis requires a high index of suspicion on the part of the surgeon.
  • Innocent local irritations will resolve in a short time with appropriate therapy; those that persist must be biopsied for tissue diagnosis.
  • Invasion and metastasis are relatively rare in this group of neoplasms; perianal Paget's disease has the highest risk of associated underlying neoplasm.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2008 Dec;51(12):1842-5 [18584248.001]
  • [Cites] J Am Acad Dermatol. 2007 Aug;57(2 Suppl):S36-7 [17637368.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 Jan;156(1):11-21 [17199561.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):587-90 [11442599.001]
  • [Cites] Dis Colon Rectum. 1997 Oct;40(10):1187-94 [9336114.001]
  • [Cites] Br J Dermatol. 1995 Jun;132(6):970-2 [7662577.001]
  • [Cites] Dis Colon Rectum. 2003 May;46(5):612-6 [12792436.001]
  • [Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]
  • (PMID = 20436838.001).
  • [ISSN] 1530-9681
  • [Journal-full-title] Clinics in colon and rectal surgery
  • [ISO-abbreviation] Clin Colon Rectal Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2780245
  • [Keywords] NOTNLM ; Anal margin cancer / diagnosis / local excision / radiation therapy / treatment options
  •  go-up   go-down



Advertisement
4. Xi Z, LinLin M, Ye T: Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system. J Clin Lab Anal; 2009;23(6):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: 102 patients with TCC, 60 with benign urinary diseases, and 60 healthy controls were included in this study.
  • RESULTS: The HE4 level was significantly increased in patients with TCC compared to patients with benign urinary diseases patients (P<0.01) and healthy controls (P<0.01), and the level of HE4 in patients with superficial TCC (Tis Ta T1) was significantly higher than that of the benign urogenital group (P<0.05)and healthy controls (P<0.05).
  • There was no difference between HE4 levels based on tumor recurrence, clinical TNM stage, lymph node metastasis, or pathological stage (P>0.05).
  • The HE4 level was also different between patients with a single tumor versus patients with multiple tumors.
  • CONCLUSIONS: HE4 may be a screening tool for early diagnosis of TCC in the urinary system, and may become a prognostic marker for TCC in the urinary system.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / blood. Epididymal Secretory Proteins / metabolism. Urologic Neoplasms / blood

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19927341.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down



5. Miragliotta V, Ipiña Z, Lefebvre-Lavoie J, Lussier JG, Theoret CL: Equine CTNNB1 and PECAM1 nucleotide structure and expression analyses in an experimental model of normal and pathological wound repair. BMC Physiol; 2008;8:1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specifically, wounds on horse limbs often develop exuberant granulation tissue which behaves clinically like a benign tumor and resembles the human keloid in that the evolving scar is trapped in the proliferative phase of repair, leading to fibrosis.

  • MedlinePlus Health Information. consumer health - Scars.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jan 1;164(1):452-62 [10605042.001]
  • [Cites] J Surg Res. 2007 Mar;138(1):141-50 [17109886.001]
  • [Cites] Blood. 2001 Mar 15;97(6):1854-60 [11238129.001]
  • [Cites] Vet Surg. 2001 May-Jun;30(3):269-77 [11340559.001]
  • [Cites] J Dermatol Sci. 2001 Nov;27(3):170-7 [11641056.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 May;282(5):C1181-90 [11940533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):200-3 [12110892.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Sep;283(3):C811-21 [12176738.001]
  • [Cites] Am J Vet Res. 2002 Nov;63(11):1564-70 [12428668.001]
  • [Cites] Mol Reprod Dev. 2003 Feb;64(2):152-65 [12506347.001]
  • [Cites] J Cell Biochem. 2003 Apr 1;88(5):1012-24 [12616538.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 28;303(1):212-8 [12646189.001]
  • [Cites] Histochem Cell Biol. 2003 May;119(5):371-81 [12750905.001]
  • [Cites] Biotechniques. 2003 Jul;35(1):72-8 [12866408.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Diabetes. 2004 Sep;53(9):2509-17 [15331568.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1359-61 [1962194.001]
  • [Cites] J Cell Biol. 1992 Sep;118(6):1511-22 [1522121.001]
  • [Cites] Science. 1993 Dec 3;262(5139):1580-2 [8248808.001]
  • [Cites] Cell. 1994 Mar 11;76(5):789-91 [7907279.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1515-24 [8568255.001]
  • [Cites] Nature. 1996 Aug 15;382(6592):638-42 [8757136.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):671-7 [9284815.001]
  • [Cites] J Clin Invest. 1999 Jan;103(1):5-9 [9884328.001]
  • [Cites] Dev Dyn. 1999 Jan;214(1):44-54 [9915575.001]
  • [Cites] FEBS Lett. 1999 Jan 15;442(2-3):178-82 [9928997.001]
  • [Cites] Equine Vet J. 1999 Jan;31(1):61-7 [9952331.001]
  • [Cites] Development. 1999 May;126(10):2285-98 [10207152.001]
  • [Cites] J Cell Sci. 1999 Sep;112 Pt 18:3005-14 [10462517.001]
  • [Cites] Lab Invest. 2005 Mar;85(3):416-25 [15654359.001]
  • [Cites] N Z Vet J. 2005 Feb;53(1):69-76 [15731837.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Apr 22;329(4):1225-33 [15766557.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):59-69 [15972952.001]
  • [Cites] Physiol Genomics. 2005 Jul 14;22(2):157-70 [15870397.001]
  • [Cites] Biol Reprod. 2005 Aug;73(2):324-33 [15829623.001]
  • [Cites] Wound Repair Regen. 2005 Sep-Oct;13(5):520-9 [16176461.001]
  • [Cites] BMC Cell Biol. 2006;7:4 [16426441.001]
  • [Cites] Clin Sci (Lond). 2006 May;110(5):587-95 [16402918.001]
  • [Cites] Am J Pathol. 2006 Jul;169(1):314-24 [16816383.001]
  • [Cites] FASEB J. 2001 Feb;15(2):362-72 [11156952.001]
  • (PMID = 18237399.001).
  • [ISSN] 1472-6793
  • [Journal-full-title] BMC physiology
  • [ISO-abbreviation] BMC Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / beta Catenin
  • [Other-IDs] NLM/ PMC2268708
  •  go-up   go-down



6. McNeill RE, Miller N, Kerin MJ: Evaluation and validation of candidate endogenous control genes for real-time quantitative PCR studies of breast cancer. BMC Mol Biol; 2007;8:107
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The expression and validity of candidate ECs (GAPDH, TFRC, ABL, PPIA, HPRT1, RPLP0, B2M, GUSB, MRPL19, PUM1 and PSMC4) was determined in 6 benign and 21 malignant primary breast cancer tissues.
  • ESR1 expression was appreciably higher in malignant compared to benign tissues and there was a significant effect of EC on the magnitude of the error associated with the relative quantity of ESR1.
  • [MeSH-minor] Biomarkers, Tumor / genetics. Estrogen Receptor alpha / genetics. Female. Gene Expression Regulation, Neoplastic. Humans. Reproducibility of Results



7. Stanley JD, Bell C, Hinkle N, Moore RA, Burns RP: The Ferguson Operating Anoscope as a minimally invasive option for the treatment of rectal tumors. Am Surg; 2010 Aug;76(8):850-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This retrospective case series evaluates the effectiveness of FOA for the excision of selected benign and malignant rectal tumors.
  • In the 97 patients evaluated, 99 FOA transanal excisions were performed for 39 adenocarcinomas, 55 benign tumors, and five carcinoid tumors.
  • The tumors were 0.5 to 13.5 cm in diameter and located an average of 6.9 cm (range, 1 to 15 cm) from the anal verge.
  • In early follow up of adenomas and favorable T1 carcinomas, FOA transanal excision has similar application, morbidity, and recurrence rates as reported for transanal endoscopic microsurgery for rectal tumors within 15 cm from the anal verge.
  • [MeSH-minor] Adenocarcinoma / surgery. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / surgery. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures / instrumentation. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20726416.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down



8. Martino P, Martino D, Palazzo S, Altomare DF, Garofalo L, Battaglia M, Selvaggi FP: Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease. Arch Ital Urol Androl; 2005 Mar;77(1):37-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental discovery of ano-rectal disease during transrectal ultrasound performed for prostatic disease.
  • In 132 cases (27%) it was shown to be a false positive, mainly due to imperfect cleansing of the anal canal; in 284 cases (58%) benign disease was demonstrated (hemorrhoids in 192 patients, abscesses in 21, perianal fistulas in 18, inflamed lymph nodes in 27, polyps in 16).
  • In 34 patients (7%) a malignant tumor was found (infiltration of the anterior rectal wall by a prostatic adenocarcinoma in 13, and a primitive adenocarcinoma of rectal origin in the remaining 21).
  • It can be concluded that transrectal US does not permit a certain diagnosis of the nature of rectal disease, but does raise a diagnostic suspicion that can orient the surgeon to schedule more invasive diagnostic investigations.

  • MedlinePlus Health Information. consumer health - Prostate Diseases.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • MedlinePlus Health Information. consumer health - Urine and Urination.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15906788.001).
  • [ISSN] 1124-3562
  • [Journal-full-title] Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica
  • [ISO-abbreviation] Arch Ital Urol Androl
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down



9. Schulte T, Kahlke V: [Mass of the pelvis minor--the coloproctological point of view]. Ther Umsch; 2007 Jul;64(7):389-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It contains the pelvic organs like the inner genital organs of women, the urinary bladder the rectum and parts of the anus.
  • The rectum is the origin of benign and malign tumors.
  • Most frequently you find under these tumors the benign adenoma and hamartoma and the malign like the rectal and anal cancer.
  • The further diagnostic work up and following therapy relates to the histology and the anatomical location of the tumor.
  • [MeSH-major] Anus Neoplasms. Pelvic Neoplasms. Rectal Neoplasms
  • [MeSH-minor] Adult. Colonoscopy. Combined Modality Therapy. Diagnosis, Differential. Endosonography. Humans. Middle Aged. Neoplasm Staging. Postoperative Care. Proctoscopy. Rectum / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948756.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down



10. Wang P, Bista RK, Khalbuss WE, Qiu W, Uttam S, Staton K, Zhang L, Brentnall TA, Brand RE, Liu Y: Nanoscale nuclear architecture for cancer diagnosis beyond pathology via spatial-domain low-coherence quantitative phase microscopy. J Biomed Opt; 2010 Nov-Dec;15(6):066028
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nanoscale nuclear architecture for cancer diagnosis beyond pathology via spatial-domain low-coherence quantitative phase microscopy.
  • Definitive diagnosis of malignancy is often challenging due to limited availability of human cell or tissue samples and morphological similarity with certain benign conditions.

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Quant Cytol Histol. 1999 Aug;21(4):347-52 [10560513.001]
  • [Cites] Opt Lett. 2010 Sep 1;35(17):2840-2 [20808342.001]
  • [Cites] Opt Lett. 2004 Jul 1;29(13):1509-11 [15259729.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):677-87 [15343274.001]
  • [Cites] J Cell Biochem. 1998 Aug 1;70(2):172-80 [9671223.001]
  • [Cites] Nat Med. 1998 Aug;4(8):882-5 [9701230.001]
  • [Cites] Nature. 1954 May 1;173(4409):821-2 [13165653.001]
  • [Cites] Opt Lett. 2005 Aug 15;30(16):2131-3 [16127933.001]
  • [Cites] Opt Lett. 2005 Sep 15;30(18):2445-7 [16196347.001]
  • [Cites] Opt Lett. 2006 Mar 15;31(6):775-7 [16544620.001]
  • [Cites] Opt Lett. 2006 May 15;31(10):1405-7 [16642120.001]
  • [Cites] Opt Lett. 2006 May 15;31(10):1462-4 [16642139.001]
  • [Cites] Opt Lett. 2009 Mar 15;34(6):767-9 [19282926.001]
  • [Cites] Opt Lett. 2009 Nov 1;34(21):3442-4 [19881621.001]
  • [Cites] Gastroenterology. 2010 Jun;138(6):2127-39 [20420950.001]
  • [Cites] J Cell Biochem. 1999;Suppl 32-33:183-91 [10629118.001]
  • (PMID = 21198202.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA152935-01; United States / NCI NIH HHS / CA / R21CA152935; United States / NCI NIH HHS / CA / R21 CA138370; United States / NCI NIH HHS / CA / R21 CA138370-01; United States / NCI NIH HHS / CA / R21 CA152935; United States / NCI NIH HHS / CA / CA138370-02; United States / NCI NIH HHS / CA / R21CA138370; United States / NCI NIH HHS / CA / CA152935-01; United States / NCI NIH HHS / CA / R21 CA138370-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3025597
  •  go-up   go-down



11. Agar NY, Malcolm JG, Mohan V, Yang HW, Johnson MD, Tannenbaum A, Agar JN, Black PM: Imaging of meningioma progression by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Anal Chem; 2010 Apr 1;82(7):2621-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often considered benign, meningiomas represent 32% of intracranial tumors with three grades of malignancy defined by the World Health Organization (WHO) histology based classification.
  • A preliminary classifier based on the support vector machine showed the ability to distinguish meningioma image spectra from the nontumor brain and from gliomas, a different type of brain tumor, and to enable class imaging of surgical tissue.

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Apr;7(4):493-6 [11283679.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18126-31 [18776051.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):5821-8 [14522905.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):981-7 [14871976.001]
  • [Cites] Anal Chem. 2004 Feb 15;76(4):1145-55 [14961749.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):245-52 [15113100.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1057-68 [15466373.001]
  • [Cites] Anal Chem. 1997 Dec 1;69(23):4751-60 [9406525.001]
  • [Cites] J Am Soc Mass Spectrom. 1999 Jan;10(1):67-71 [9888186.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):396-401 [15549107.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9093-100 [15604278.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):394-401 [15677390.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7674-81 [16140934.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):7843-8 [16912155.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1720-6 [16546995.001]
  • [Cites] Nature. 2006 Dec 7;444(7120):756-60 [17051156.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Anal Chem. 2007 Oct 1;79(19):7416-23 [17822313.001]
  • [Cites] J Cell Mol Med. 2008 Sep-Oct;12(5A):1535-47 [18266982.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • (PMID = 20196536.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / U41 RR019703; United States / NIBIB NIH HHS / EB / U54 EB005149-030003; United States / NIBIB NIH HHS / EB / U54 EB005149; United States / NCRR NIH HHS / RR / P41 RR-13218; United States / NCRR NIH HHS / RR / RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218-108435; United States / NCRR NIH HHS / RR / P41 RR013218; United States / NIBIB NIH HHS / EB / EB005149-030003
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS184740; NLM/ PMC2852177
  •  go-up   go-down



12. Driemel O, Dahse R, Berndt A, Pistner H, Hakim SG, Zardi L, Reichert TE, Kosmehl H: High-molecular tenascin-C as an indicator of atypical cells in oral brush biopsies. Clin Oral Investig; 2007 Mar;11(1):93-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour-invasion like wound healing is characterised by the formation of an extracellular matrix with a high tenascin-C content.
  • Analysis using antibody BC2 indicates that especially the high-molecular tenascin-C (hm tn-C) variants are typically tumour-associated, while distribution in normal tissue is restrictive.
  • Conventional cytology produced four false-positives when identifying atypical cells in brush biopsies of inflammatory/benign hyperproliferative mucosa (specificity 96%), while 10 in 52 carcinomas and three of eight recurrences were not identified (sensitivity 78%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Biopsy / methods. Carcinoma, Squamous Cell / pathology. Mouth Neoplasms / pathology. Tenascin / analysis
  • [MeSH-minor] Epithelial Cells / pathology. Humans. Immunoenzyme Techniques. Mouth Mucosa / pathology. Neoplasm Invasiveness / pathology. Prospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Cell Pathol. 2003;25(3):139-46 [12775918.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):986-90 [15094113.001]
  • [Cites] Br J Cancer. 2006 Apr 24;94(8):1170-5 [16622441.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):505-10 [10762653.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1419-26 [11745218.001]
  • [Cites] J Am Dent Assoc. 1999 Oct;130(10):1445-57 [10570588.001]
  • [Cites] J Oral Pathol Med. 2006 Sep;35(8):520; author reply 520-2 [16918607.001]
  • [Cites] Int J Cancer. 2002 Aug 20;100(6):719-22 [12209613.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Oncology. 2003;64(3):245-50 [12697965.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Sep;96(3):252 [14515857.001]
  • [Cites] Anal Cell Pathol. 2001;22(4):211-21 [11564897.001]
  • [Cites] Biochem Cell Biol. 1997;75(6):759-69 [9599665.001]
  • [Cites] J Pathol. 2003 Jul;200(4):429-47 [12845611.001]
  • [Cites] J Pathol. 2004 Jul;203(3):771-9 [15221936.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):680-7 [9495234.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):824-8 [15288838.001]
  • [Cites] J Oral Pathol Med. 2006 Jan;35(1):58-60 [16393256.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Cytopathology. 2007 Dec;18(6):348-55 [18031447.001]
  • [Cites] J Oral Pathol Med. 1994 Nov;23(10):446-50 [7532219.001]
  • [Cites] J Oral Pathol Med. 2004 Aug;33(7):398-404 [15250831.001]
  • [Cites] Histochem Cell Biol. 2006 Jul;126(1):125-31 [16344911.001]
  • [Cites] Oral Oncol. 2004 Sep;40(8):829-34 [15288839.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 May;127(5):286-92 [11355143.001]
  • [Cites] Oral Oncol. 2002 Jun;38(4):332-6 [12076695.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • [Cites] Gen Dent. 2002 Nov-Dec;50(6):500-3 [12572180.001]
  • [Cites] Mund Kiefer Gesichtschir. 2004 Jul;8(4):229-36 [15293118.001]
  • (PMID = 17111122.001).
  • [ISSN] 1432-6981
  • [Journal-full-title] Clinical oral investigations
  • [ISO-abbreviation] Clin Oral Investig
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tenascin
  •  go-up   go-down



13. Nagy A, Kovacs T, Lóderer Z: Experiences with PPH gun stapled ileo or coloanal anastomoses after ultralow rectal resections and proctocolectomies with J pouch reconstructions. Acta Chir Iugosl; 2006;53(2):61-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On 47 totalcolectomised FAP and UC patients and 9 low rectal benign or clinically T1 or T2N0 rectal tumor resection there was only 5 radiologically proven anastomotic leakadge without serious septic complications.
  • The anal sphincter function after 6 month of the ileoanal anastomosis remained good in 33/39 and acceptable in 6 cases, if the sphincter function was intact praeoperatively.
  • After the ultra low rectal resections all patients kept the normal anal shpincter function.
  • [MeSH-major] Anal Canal / surgery. Colon / surgery. Ileum / surgery. Proctocolectomy, Restorative. Rectum / surgery. Surgical Stapling

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17139887.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down



14. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
  • As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood



15. Branchini G, Schneider L, Cericatto R, Capp E, Brum IS: Progesterone receptors A and B and estrogen receptor alpha expression in normal breast tissue and fibroadenomas. Endocrine; 2009 Jun;35(3):459-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibroadenomas are the most common benign breast tumors, occurring mainly in young women.
  • Their responses to the hormonal environment are similar to those of normal breast tissue, which suggests that steroid receptors may play a role in tumor development.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Steroid Biochem Mol Biol. 2006 Mar;98(4-5):218-27 [16466914.001]
  • [Cites] Breast J. 1999 Jul;5(4):256-261 [11348297.001]
  • [Cites] Steroids. 2000 Oct-Nov;65(10-11):571-7 [11108861.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):287-99 [12846413.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):193-202 [12790782.001]
  • [Cites] Breast. 2003 Oct;12 (5):302-7 [14659144.001]
  • [Cites] Cancer Res. 1993 Sep 1;53(17):4071-4 [8395336.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5209-18 [11717311.001]
  • [Cites] Steroids. 2003 Nov;68(10-13):771-8 [14667967.001]
  • [Cites] J Clin Pathol. 2001 Jan;54(1):37-41 [11271786.001]
  • [Cites] Endocr Rev. 1997 Aug;18(4):502-19 [9267762.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2000 Jul;5(3):325-38 [14973394.001]
  • [Cites] Mol Endocrinol. 1999 Oct;13(10):1657-71 [10517668.001]
  • [Cites] Cell. 1997 Feb 7;88(3):323-31 [9039259.001]
  • [Cites] Maturitas. 2004 Sep 24;49(1):16-24 [15351092.001]
  • [Cites] Endocrine. 2009 Feb;35(1):118-22 [19002614.001]
  • [Cites] Steroids. 2005 Mar;70(3):153-60 [15763593.001]
  • [Cites] Breast Cancer Res. 2002;4(5):187-90 [12223122.001]
  • [Cites] Br J Cancer. 1992 Apr;65(4):601-7 [1562470.001]
  • [Cites] Cell Mol Life Sci. 2008 Nov;65(23 ):3839-50 [18850315.001]
  • [Cites] Mol Endocrinol. 2005 Nov;19(11):2713-35 [15976005.001]
  • [Cites] Epidemiol Rev. 1997;19(2):310-27 [9494790.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):394-9 [15099952.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2006 Nov;129(1):77-83 [16460873.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):371-4 [11986344.001]
  • [Cites] Breast Cancer Res Treat. 2002 Mar;72(2):163-72 [12038707.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jan;176(1 Pt 1):123-8 [9024102.001]
  • [Cites] EMBO J. 1990 May;9(5):1603-14 [2328727.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Curr Probl Diagn Radiol. 2007 Mar-Apr;36(2):66-82 [17331838.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Braz J Med Biol Res. 1996 Dec;29(12):1593-7 [9222417.001]
  • [Cites] J Mol Endocrinol. 2000 Feb;24(1):33-41 [10656995.001]
  • [Cites] Cancer Res. 2002 Sep 1;62(17):4849-53 [12208729.001]
  • [Cites] Mol Endocrinol. 2005 Mar;19(3):574-87 [15563544.001]
  • [Cites] Jpn J Cancer Res. 2001 Mar;92(3):302-8 [11267940.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Aug;84(8):2963-71 [10443705.001]
  • [Cites] Endocr Relat Cancer. 2002 Mar;9(1):1-13 [11914179.001]
  • (PMID = 19367380.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Receptors, Progesterone; 0 / progesterone receptor A; 0 / progesterone receptor B
  •  go-up   go-down



16. Celis JE, Gromova I, Cabezón T, Gromov P, Shen T, Timmermans-Wielenga V, Rank F, Moreira JM: Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease. Mol Oncol; 2007 Dec;1(3):321-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, we presented evidence--based on the analysis of benign hyperproliferative lesions of the breast--for the presence of cells that express the stem cell marker cytokeratin (CK) 15 in combination with CK19, a protein widely expressed by mammary epithelial cells.
  • The remaining tumor was mainly composed of cells expressing both CK15 and CK19 (CK15+/CK19+), but it also contained invasive areas with cells expressing only one of these makers (CK15+/CK19- and CK15-/CK19+ cells).
  • To address the relationship between putative luminal progenitor/amplified CK15+ cells and malignant disease, and to determine whether cells/lesions lose expression of CK15 as a result of tumour initiation and/or progression, we searched among our sample set for carcinomas in which invasive tumor areas co-existed with non-malignant cells and hyperproliferative and known pre-malignant lesions.
  • Only one such tumour was found (T71), a CK15-/CK19+/p53+ carcinoma that contained p53 negative non-malignant epithelial cells exhibiting a variety of, CK15/CK19 cellular phenotypes (CK15+/CK19+; CK15+/CK19-; CK15-/CK19+; CK15-/CK19-), often associated with simple columnar cells.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Female. Fluorescent Antibody Technique, Direct. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness



17. Woenckhaus M, Grepmeier U, Werner B, Schulz C, Rockmann F, Wild PJ, Röckelein G, Blaszyk H, Schuierer M, Hofstaedter F, Hartmann A, Dietmaier W: Microsatellite analysis of pleural supernatants could increase sensitivity of pleural fluid cytology. J Mol Diagn; 2005 Oct;7(4):517-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A common diagnostic problem lies in distinguishing malignant from benign pleural effusions using routine cytological evaluation.
  • We studied pleural fluid samples obtained from 14 patients with histologically confirmed malignancy and from 6 patients with benign pleural effusions using 12 microsatellite markers from 8 different chromosomal regions.
  • Microsatellite analyses of pleural fluid supernatants showed genetic alterations in tumor patients only.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Genetic Markers / genetics. Humans. Loss of Heterozygosity / genetics. Male. Middle Aged. Neoplasms / diagnosis. Neoplasms / genetics. Neoplasms / pathology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Health Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1999 Jan 21;18(3):643-50 [9989814.001]
  • [Cites] Eur Respir J. 1997 Feb;10(2):476-81 [9042652.001]
  • [Cites] Pathol Res Pract. 1996 Dec;192(12):1206-10 [9182290.001]
  • [Cites] J Oral Pathol Med. 1997 Aug;26(7):322-6 [9250932.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 17;89(18):1366-73 [9308707.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4749-56 [9354436.001]
  • [Cites] Ann Thorac Surg. 1997 Oct;64(4):941-4 [9354505.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2028-32 [10580028.001]
  • [Cites] Anal Cell Pathol. 1999;19(1):7-20 [10661621.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):341-7 [10023701.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 17;91(4):332-9 [10050866.001]
  • [Cites] Diagn Cytopathol. 1999 Jun;20(6):350-7 [10352907.001]
  • [Cites] Surg Oncol Clin N Am. 1999 Oct;8(4):641-56, vi [10452932.001]
  • [Cites] Clin Cancer Res. 1999 Sep;5(9):2297-303 [10499596.001]
  • [Cites] Cancer Metastasis Rev. 1999;18(1):65-73 [10505546.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7335-46 [15534110.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2502-9 [15814626.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1631-43 [15742334.001]
  • [Cites] Internist (Berl). 1996 Sep;37(9):959-68; quiz 968 [8964697.001]
  • [Cites] Anal Cell Pathol. 1996 Nov;12(2):85-98 [8986293.001]
  • [Cites] Hum Pathol. 1999 Dec;30(12):1508-14 [10667431.001]
  • [Cites] Cancer Res. 2000 Feb 1;60(3):707-11 [10676657.001]
  • [Cites] Cancer Res. 2000 May 1;60(9):2488-91 [10811129.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):448-55 [10821492.001]
  • [Cites] Cancer Res. 2000 Jun 15;60(12):3155-9 [10866304.001]
  • [Cites] Cancer. 2000 Aug 25;90(4):258-63 [10966568.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):5954-8 [11085511.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):200-4 [11146445.001]
  • [Cites] Cancer. 2001 Feb 25;93(1):68-72 [11241268.001]
  • [Cites] Cancer Lett. 2001 Apr 10;165(1):63-9 [11248420.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4675-8 [11406535.001]
  • [Cites] Chest. 2001 Jul;120(1):50-4 [11451815.001]
  • [Cites] Diagn Cytopathol. 2001 Oct;25(4):225-30 [11599105.001]
  • [Cites] Cancer. 2001 Oct 25;93(5):293-308 [11668464.001]
  • [Cites] Am J Respir Crit Care Med. 2001 Oct 1;164(7):1312-8 [11673227.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):35-40 [11801538.001]
  • [Cites] Cancer Res. 2002 Apr 15;62(8):2370-7 [11956099.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):210-9 [11990857.001]
  • [Cites] Eur Urol. 2002 Jun;41(6):668-76 [12074786.001]
  • [Cites] Anal Cell Pathol. 2002;24(1):5-15 [12122279.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):534-41 [12124802.001]
  • [Cites] Lab Invest. 2002 Sep;82(9):1147-53 [12218075.001]
  • [Cites] Diagn Cytopathol. 2002 Oct;27(4):210-3 [12357497.001]
  • [Cites] Ann Pathol. 2002 Sep;22(4):277-88 [12410150.001]
  • [Cites] J Gastroenterol. 2002;37(10):831-9 [12424567.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):172-7 [12800191.001]
  • [Cites] Pathol Res Pract. 2003;199(6):355-62 [12924435.001]
  • [Cites] Eur J Haematol. 2003 Sep;71(3):174-8 [12930317.001]
  • [Cites] Histol Histopathol. 2003 Oct;18(4):1053-7 [12973674.001]
  • [Cites] Biogerontology. 2003;4(4):233-50 [14501188.001]
  • [Cites] Int J Oncol. 2003 Nov;23(5):1357-63 [14532977.001]
  • [Cites] Clin Lab Med. 2003 Sep;23(3):729-54, viii [14560537.001]
  • [Cites] Pancreas. 2004 Jan;28(1):13-9 [14707724.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jan;83(2):119-28 [14997042.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):33-42 [15013581.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2716-26 [15048096.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Clin Med. 2004 May-Jun;4(3):207-10 [15244350.001]
  • [Cites] Breast Cancer Res Treat. 2004 Sep;87(1):23-31 [15377848.001]
  • [Cites] Int J Cancer. 2004 Nov 20;112(4):643-6 [15382045.001]
  • [Cites] Diagn Cytopathol. 2004 Oct;31(4):246-54 [15452897.001]
  • [Cites] Cancer Genet Cytogenet. 1986 Jan 15;19(3-4):271-9 [3943048.001]
  • [Cites] Eur J Respir Dis. 1985 Nov;67(5):326-34 [4085584.001]
  • [Cites] Cancer Res. 1990 Nov 15;50(22):7166-73 [1977514.001]
  • [Cites] Mod Pathol. 1991 May;4(3):320-4 [2068057.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):534-7 [1399132.001]
  • [Cites] Mol Cell Endocrinol. 1993 Apr;92(2):153-60 [8319825.001]
  • [Cites] Nat Med. 1996 Sep;2(9):1035-7 [8782464.001]
  • [Cites] Genes Chromosomes Cancer. 1997 Nov;20(3):268-74 [9365834.001]
  • [Cites] Electrophoresis. 1997 Sep;18(10):1742-9 [9372265.001]
  • [Cites] Ann Oncol. 1998 Jan;9(1):113-6 [9541693.001]
  • [Cites] Gynecol Oncol. 1999 Jan;72(1):3-9 [9889022.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):83-95 [9916922.001]
  • (PMID = 16237222.001).
  • [ISSN] 1525-1578
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers
  • [Other-IDs] NLM/ PMC1888495
  •  go-up   go-down



18. Bistulfi G, Vandette E, Matsui S, Smiraglia DJ: Mild folate deficiency induces genetic and epigenetic instability and phenotype changes in prostate cancer cells. BMC Biol; 2010 Jan 21;8:6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: We studied the consequences of long-term, mild folate depletion in a model comprised of three syngenic cell lines derived from the transgenic adenoma of the mouse prostate (TRAMP) model, recapitulating different stages of prostate cancer; benign, transformed and metastatic.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genomics. 1999 Jun 15;58(3):254-62 [10373323.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6872-80 [15286716.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):981-90 [15695236.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2703-9 [16251634.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15785-90 [16243968.001]
  • [Cites] Mutat Res. 2006 Jan 29;593(1-2):80-7 [16144704.001]
  • [Cites] Gut. 2006 Oct;55(10):1387-9 [16966698.001]
  • [Cites] Genome Res. 2006 Oct;16(10):1222-30 [16954539.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10308-14 [17079450.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10349-56 [17079455.001]
  • [Cites] Exp Oncol. 2006 Sep;28(3):178-86 [17080009.001]
  • [Cites] J Nutr. 2007 Jan;137(1 Suppl):216S-222S [17182829.001]
  • [Cites] Nat Rev Drug Discov. 2007 May;6(5):373-90 [17464296.001]
  • [Cites] JAMA. 2007 Jun 6;297(21):2351-9 [17551129.001]
  • [Cites] Anticancer Agents Med Chem. 2007 Sep;7(5):524-42 [17896913.001]
  • [Cites] Nucleic Acids Res. 2007;35(18):e119 [17855397.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] BMC Genomics. 2007;8:446 [18053125.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Nutr Biochem. 2008 May;19(5):328-35 [17681772.001]
  • [Cites] J Natl Cancer Inst. 2009 Mar 18;101(6):432-5 [19276452.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2888-97 [19417083.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Nutr Cancer. 2000;37(2):245-51 [11142099.001]
  • [Cites] Genomics. 2004 Oct;84(4):647-60 [15475242.001]
  • [Cites] Biochem J. 1969 Nov;115(2):241-7 [5378381.001]
  • [Cites] Am J Hum Genet. 1979 Mar;31(2):125-35 [36752.001]
  • [Cites] Clin Chem. 1988 Nov;34(11):2357-9 [3141087.001]
  • [Cites] Cell Prolif. 1993 Jul;26(4):327-36 [8343561.001]
  • [Cites] Biochem Pharmacol. 1995 Oct 26;50(9):1433-43 [7503794.001]
  • [Cites] DNA Cell Biol. 1996 Mar;15(3):255-62 [8634154.001]
  • [Cites] Cancer Lett. 1997 May 1;115(1):31-8 [9097976.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3325-30 [9269988.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1413-9 [11440994.001]
  • [Cites] Oncogene. 2002 May 30;21(24):3909-16 [12032829.001]
  • [Cites] Methods. 2002 Jun;27(2):144-9 [12095273.001]
  • [Cites] Cancer Lett. 2002 Dec 10;187(1-2):69-75 [12359353.001]
  • [Cites] Nat Genet. 2002 Nov;32(3):453-8 [12355068.001]
  • [Cites] Carcinogenesis. 1997 Nov;18(11):2071-6 [9395204.001]
  • [Cites] Carcinogenesis. 2003 Jan;24(1):81-90 [12538352.001]
  • [Cites] Hum Mol Genet. 2003 Apr 1;12(7):791-801 [12651874.001]
  • [Cites] Biochem Soc Trans. 2003 Apr;31(2):375-80 [12653642.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 1):3740S-3747S [14608108.001]
  • [Cites] Mutat Res. 2004 Apr 14;548(1-2):53-9 [15063136.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Nov;36(11):2125-30 [15313459.001]
  • [Cites] Anal Chem. 2005 Jan 15;77(2):504-10 [15649046.001]
  • (PMID = 20092614.001).
  • [ISSN] 1741-7007
  • [Journal-full-title] BMC biology
  • [ISO-abbreviation] BMC Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016056; United States / NCI NIH HHS / CA / R21 CA131646; United States / NCI NIH HHS / CA / CA016056; United States / NCI NIH HHS / CA / R21 CA121216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 6R795CQT4H / 5-Methylcytosine
  • [Other-IDs] NLM/ PMC2845099
  •  go-up   go-down



19. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down



20. Zon G, Barker MA, Kaur P, Groshen S, Jones LW, Imam SA, Boyd VL: Formamide as a denaturant for bisulfite conversion of genomic DNA: Bisulfite sequencing of the GSTPi and RARbeta2 genes of 43 formalin-fixed paraffin-embedded prostate cancer specimens. Anal Biochem; 2009 Sep 15;392(2):117-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Detection of methylated GSTPi and RARbeta2 genes was significantly associated with primary prostate cancer as compared with the benign prostate (Fisher's exact test, P < 0.001).
  • [MeSH-major] DNA, Neoplasm / chemistry. Formamides / pharmacology. Genome, Human. Glutathione S-Transferase pi / genetics. Prostatic Neoplasms / genetics. Receptors, Retinoic Acid / genetics. Sequence Analysis, DNA / methods
  • [MeSH-minor] Base Sequence. Biomarkers, Tumor / genetics. Biopsy. DNA Methylation. Formaldehyde. Humans. Male. Molecular Sequence Data. Nucleic Acid Denaturation / drug effects. Paraffin Embedding. Sulfites



21. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.
  • CONCLUSION: LPA is a better biomarker for diagnosis of epithelial ovarian cancer compared to CA-125.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down



22. Yili Z, Xiaoyan H, Hongwen D, Yun Z, Xin C, Peng W, Youmin G: The value of diffusion-weighted imaging in assessing the ADC changes of tissues adjacent to breast carcinoma. BMC Cancer; 2009;9:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To define a threshold value of apparent diffusion coefficient (ADC) with which malignant breast lesions can be distinguished from benign lesions, and to evaluate the ADC change of peri-tumor tissue in breast carcinoma by echo planar-diffusion weighted imaging (EPI-DWI).
  • The ADC values were compared between malignant and benign lesions.
  • The ADC values of malignant lesion and layered peri-tumor tissues (from innermost layer 1 to outermost layer 4 with 5 mm every layer) in different directions were compared and the ADC values among different layers were compared.
  • RESULTS: The ADC value of 35 malignant lesions was statistically lower than that of 22 benign lesions (P < 0.05).
  • The ADC value of malignant lesions was statistically lower than that of peri-tumor tissues in different directions (P < 0.05).
  • For peri-tumor tissues, the ADC values increased gradually from layer 1 to layer 4 and there was a significant difference between the ADC values of layer 1 and layer 2 (P < 0.05); while from layer 2 outwards, there was no statistical difference among different layers.
  • CONCLUSION: ADC value was a sensitive and specific parameter that could help to differentiate benign and malignant breast lesions.
  • [MeSH-major] Breast Diseases / diagnosis. Breast Neoplasms / diagnosis. Echo-Planar Imaging / methods
  • [MeSH-minor] Adult. Aged. Breast / pathology. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Ductal, Breast / pathology. Diagnosis, Differential. Female. Fibroadenoma / diagnosis. Fibroadenoma / pathology. Humans. Hyperplasia. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 23;338(3):1353-8 [16269133.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Breast J. 2006 Jan-Feb;12(1):28-36 [16409584.001]
  • [Cites] Cir Esp. 2006 Jan;79(1):3-9 [16426527.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1626-9 [16570359.001]
  • [Cites] Anal Biochem. 2006 Aug 1;355(1):117-24 [16756932.001]
  • [Cites] Magn Reson Imaging. 2006 Sep;24(7):843-7 [16916701.001]
  • [Cites] J Magn Reson Imaging. 2006 Aug;24(2):319-24 [16786565.001]
  • [Cites] Breast J. 2006 Sep-Oct;12(5 Suppl 2):S174-80 [16958998.001]
  • [Cites] Gut. 2006 Nov;55(11):1598-605 [16682430.001]
  • [Cites] Magn Reson Imaging Clin N Am. 2006 Aug;14(3):305-28, v [17098173.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6626-36 [17121881.001]
  • [Cites] Radiol Med. 2006 Dec;111(8):1124-33 [17171522.001]
  • [Cites] Histopathology. 2007 Jan;50(2):232-42 [17222252.001]
  • [Cites] Ai Zheng. 2007 Feb;26(2):168-71 [17298747.001]
  • [Cites] J Magn Reson Imaging. 2007 Jun;25(6):1101-12 [17520731.001]
  • [Cites] J Comput Assist Tomogr. 2007 May-Jun;31(3):449-54 [17538295.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):335-43 [11241804.001]
  • [Cites] Radiologe. 2002 Jan;42(1):1-5 [11930535.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):926-33 [12569592.001]
  • [Cites] Br J Plast Surg. 2003 Jul;56(5):462-70 [12890459.001]
  • [Cites] Oncology (Williston Park). 2003 Nov;17(11):1511-33; discussion 1533-4, 1539, 1542 passim [14682107.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):39-44 [14732766.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2269-80 [15160329.001]
  • [Cites] Annu Rev Med. 1996;47:285-301 [8712782.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] Int J Cancer. 2005 Mar 1;113(6):1022-5 [15515012.001]
  • [Cites] Rofo. 2005 Jan;177(1):114-8 [15657829.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5(6):425-38 [15748463.001]
  • [Cites] Am Surg. 2005 Jan;71(1):22-7; discussion 27-8 [15757052.001]
  • [Cites] Magn Reson Med Sci. 2002 Jul 1;1(2):73-80 [16082129.001]
  • [Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Aug;5(4):737-45 [16111473.001]
  • [Cites] Magn Reson Med Sci. 2005;4(1):35-42 [16127252.001]
  • [Cites] Breast Cancer Res Treat. 2005 Dec;94(3):195-8 [16258704.001]
  • (PMID = 19144163.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2633008
  •  go-up   go-down



23. Ciordia S, de Los Ríos V, Albar JP: Contributions of advanced proteomics technologies to cancer diagnosis. Clin Transl Oncol; 2006 Aug;8(8):566-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contributions of advanced proteomics technologies to cancer diagnosis.
  • This discipline incorporates technologies that can be applied to complex biosystems such as serum and tissue in order to characterize the content of, and changes in, the proteome induced by physiological changes, benign or pathologic.
  • These tools include 2-DE, 2D-DIGE, ICAT, protein arrays, MudPIT and mass spectrometries including SELDI-TOF.
  • [MeSH-major] Biomarkers, Tumor / analysis. Neoplasms / diagnosis. Neoplasms / genetics. Proteome / analysis. Proteomics / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 May 5;819(1):59-66 [15797521.001]
  • [Cites] Mol Cell Proteomics. 2002 Feb;1(2):117-24 [12096129.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Arch Pathol Lab Med. 2002 Dec;126(12):1518-26 [12456215.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):399-409 [14726492.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] J Proteome Res. 2005 Mar-Apr;4(2):377-86 [15822913.001]
  • [Cites] J Am Soc Mass Spectrom. 2003 Jul;14 (7):760-5 [12837598.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):200-8 [15113095.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1272-5 [12881441.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):195-200 [16327996.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] World J Gastroenterol. 2006 Mar 14;12(10):1536-44 [16570345.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):6029-33 [11507047.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1073-85 [15709174.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):367-78 [14990683.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):267-75 [12671665.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1898-905 [16755300.001]
  • [Cites] Cancer Lett. 2005 Aug 26;226(2):101-6 [16039949.001]
  • [Cites] Brief Funct Genomic Proteomic. 2004 Nov;3(3):220-39 [15642186.001]
  • [Cites] Blood. 2005 May 1;105(9):3722-30 [15650054.001]
  • [Cites] Proteomics. 2006 Apr;6(8):2600-8 [16502466.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):157-71 [16215274.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] World J Gastroenterol. 2004 Nov 1;10(21):3127-31 [15457557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12343-8 [14523236.001]
  • [Cites] Methods Mol Biol. 1999;112:531-52 [10027275.001]
  • [Cites] J Pathol. 2005 May;206(1):39-45 [15772986.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7500-10 [15569980.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Cancer Sci. 2005 Mar;96(3):197-201 [15771624.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):282-8 [15113105.001]
  • [Cites] Am J Pathol. 2002 Oct;161(4):1223-33 [12368196.001]
  • [Cites] Mol Cell Proteomics. 2003 Jul;2(7):443-52 [12824440.001]
  • [Cites] Proteomics. 2005 May;5(7):1953-66 [15816004.001]
  • [Cites] Mol Cell Proteomics. 2006 Mar;5(3):433-43 [16319398.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):845-56 [15107802.001]
  • [Cites] Methods Mol Biol. 2005;293:255-67 [16028425.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Sep 12;309(1):18-25 [12943657.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):670-8 [15098007.001]
  • [Cites] J Proteome Res. 2006 May;5(5):1143-54 [16674103.001]
  • [Cites] BMC Cancer. 2006 Mar 16;6:68 [16542425.001]
  • [Cites] Prostate Cancer Prostatic Dis. 1999 Dec;2(5/6):264-276 [12497173.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Proteomics. 2003 Mar;3(3):254-64 [12627378.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):311-26 [14718574.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Proteomics. 2005 Nov;5(17):4589-96 [16237736.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Jan;130(1):98-104 [14732777.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):791-6 [15609313.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8312-20 [16322290.001]
  • [Cites] Anticancer Res. 2005 Mar-Apr;25(2B):1197-203 [15865066.001]
  • [Cites] Clin Chem Lab Med. 2003 Dec;41(12):1562-70 [14708880.001]
  • [Cites] BMC Cancer. 2005 Jan 19;5:8 [15656915.001]
  • [Cites] Technol Cancer Res Treat. 2006 Feb;5(1):67-72 [16417404.001]
  • [Cites] Clin Chim Acta. 2005 Jul 24;357(2):113-22 [15941565.001]
  • [Cites] Neurol Res. 2006 Mar;28(2):155-63 [16551433.001]
  • [Cites] Electrophoresis. 1997 Oct;18(11):2071-7 [9420172.001]
  • [Cites] Protein Expr Purif. 2000 Jun;19(1):12-21 [10833385.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 [14573703.001]
  • [Cites] Proteomics. 2006 Jan;6(2):697-708 [16252305.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7585-93 [11606398.001]
  • [Cites] J Proteome Res. 2004 Mar-Apr;3(2):289-95 [15113106.001]
  • [Cites] Dis Markers. 2003-2004;19(1):33-9 [14757945.001]
  • [Cites] Hum Reprod. 2003 May;18(5):915-24 [12721162.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8380-5 [15623616.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):54-64 [16819514.001]
  • [Cites] Nat Biotechnol. 1999 Oct;17(10):994-9 [10504701.001]
  • [Cites] Hepatology. 2005 Jan;41(1):40-7 [15690480.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):43-52 [14734450.001]
  • [Cites] Clin Chem. 2005 Dec;51(12):2229-35 [16223889.001]
  • [Cites] Nat Methods. 2005 Sep;2(9):691-7 [16118640.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Feb 5;815(1-2):215-25 [15652811.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):5-8 [10637622.001]
  • [Cites] Anal Cell Pathol. 2000;21(1):1-9 [11254220.001]
  • [Cites] Clin Sci (Lond). 2005 May;108(5):369-83 [15831087.001]
  • [Cites] Clin Chem. 2005 Apr;51(4):695-707 [15695329.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9390-5 [10920198.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):757-63 [10701260.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1213-22 [16083271.001]
  • [Cites] J Proteome Res. 2004 May-Jun;3(3):636-43 [15253447.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14229-34 [14623978.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):377-83 [15671041.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2904-11 [12912935.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):638-44 [15286743.001]
  • [Cites] FASEB J. 2005 Jul;19(9):1125-7 [15985535.001]
  • [Cites] Cancer. 2004 May 1;100(9):1814-22 [15112261.001]
  • [Cites] Int J Oncol. 2004 Jun;24(6):1513-22 [15138595.001]
  • [Cites] Proteomics. 2003 Dec;3(12):2310-6 [14673781.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):860-8 [14871961.001]
  • [Cites] Electrophoresis. 1997 Mar-Apr;18(3-4):533-7 [9150937.001]
  • [Cites] Electrophoresis. 2006 Apr;27(8):1641-50 [16550499.001]
  • [Cites] Clin Chem Lab Med. 2005;43(12):1314-20 [16309366.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Mol Cell Proteomics. 2006 Jun;5(6):1119-30 [16554294.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2365-6 [15384161.001]
  • [Cites] Pathol Res Pract. 2005;201(12):763-70 [16308101.001]
  • [Cites] Biol Mass Spectrom. 1993 Jun;22(6):338-45 [8329463.001]
  • (PMID = 16952845.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Proteome
  • [Number-of-references] 108
  •  go-up   go-down



24. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C, Chiti F: A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol; 2010 Feb;6(2):140-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe two types of oligomers formed by the HypF-N protein that are morphologically and tinctorially similar, as detected with atomic force microscopy and thioflavin T assays, though one is benign when added to cell cultures whereas the other is toxic.
  • [MeSH-minor] Cell Line, Tumor. Cell Membrane / metabolism. Cell Survival. Humans. Hydrophobic and Hydrophilic Interactions. Microscopy, Atomic Force. Protein Binding. Protein Conformation

  • COS Scholar Universe. author profiles.
  • BioCyc. gene/protein/disease-specific - hypF .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20081829.001).
  • [ISSN] 1552-4469
  • [Journal-full-title] Nature chemical biology
  • [ISO-abbreviation] Nat. Chem. Biol.
  • [Language] eng
  • [Databank-accession-numbers] PDB/ 1GXU
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Escherichia coli Proteins; EC 2.1.3.- / Carboxyl and Carbamoyl Transferases; EC 2.1.3.- / hypF protein, E coli
  •  go-up   go-down



25. Almsherqi Z, Hyde S, Ramachandran M, Deng Y: Cubic membranes: a structure-based design for DNA uptake. J R Soc Interface; 2008 Sep 6;5(26):1023-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cubic membranes thus may offer a new, potentially benign medium for gene transfection.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1995 Aug 11;270(32):18997-9007 [7642560.001]
  • [Cites] FEBS Lett. 1995 Aug 1;369(1):13-7 [7641875.001]
  • [Cites] Curr Opin Struct Biol. 1997 Oct;7(5):661-8 [9345624.001]
  • [Cites] Biosci Rep. 1997 Dec;17(6):507-20 [9561295.001]
  • [Cites] Chemphyschem. 2004 Oct 18;5(10):1619-23 [15535566.001]
  • [Cites] Bioconjug Chem. 2005 Nov-Dec;16(6):1335-9 [16287225.001]
  • [Cites] Biochim Biophys Acta. 2005 Dec 30;1746(3):349-63 [16440447.001]
  • [Cites] J Cell Biol. 2006 Jun 19;173(6):839-44 [16785319.001]
  • [Cites] J Agric Food Chem. 2007 Mar 7;55(5):1915-22 [17263546.001]
  • [Cites] Langmuir. 2007 Nov 20;23(24):12003-9 [17949111.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12293-8 [10535915.001]
  • [Cites] J Struct Biol. 1999 Oct;127(3):231-9 [10544048.001]
  • [Cites] Nature. 2003 Mar 6;422(6927):37-44 [12621426.001]
  • [Cites] J Am Chem Soc. 2003 Jun 18;125(24):7188-9 [12797787.001]
  • [Cites] Mol Ther. 2003 Dec;8(6):957-63 [14664798.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Gene Ther. 1996 Nov;3(11):1010-7 [9044741.001]
  • (PMID = 18270148.001).
  • [ISSN] 1742-5689
  • [Journal-full-title] Journal of the Royal Society, Interface
  • [ISO-abbreviation] J R Soc Interface
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Phosphorothioate Oligonucleotides; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2607430
  •  go-up   go-down



26. Sekine Y, Demosky SJ, Stonik JA, Furuya Y, Koike H, Suzuki K, Remaley AT: High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol Cancer Res; 2010 Sep;8(9):1284-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In human prostate biopsy samples, ABCA1 mRNA expression was ∼2-fold higher in the androgen deprivation therapy group than in subjects with benign prostatic hyperplasia or pretreatment prostate cancer groups.
  • [MeSH-minor] ATP Binding Cassette Transporter 1. Androgens / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cholesterol / metabolism. Enzyme Activation / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic / drug effects. Humans. Intracellular Space / drug effects. Intracellular Space / metabolism. Male. Proto-Oncogene Proteins c-akt / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / metabolism. Simvastatin / pharmacology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. CHOLESTEROL .
  • Hazardous Substances Data Bank. SIMVASTATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 AACR.
  • [Cites] Curr Opin Lipidol. 2004 Dec;15(6):659-65 [15529025.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7682-5 [15520169.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):959-68 [15776112.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):883-91 [15705602.001]
  • [Cites] Am J Epidemiol. 2005 Aug 15;162(4):318-25 [16014776.001]
  • [Cites] Trends Cardiovasc Med. 2005 Oct;15(7):265-71 [16226682.001]
  • [Cites] Biochem Biophys Res Commun. 2006 May 26;344(1):226-32 [16600185.001]
  • [Cites] Mol Cancer Ther. 2006 Sep;5(9):2310-6 [16985065.001]
  • [Cites] J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25 [17179483.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):463-71 [17252538.001]
  • [Cites] Prostate. 2007 Jul 1;67(10):1061-9 [17469127.001]
  • [Cites] Clin Chim Acta. 2007 Aug;383(1-2):78-84 [17512923.001]
  • [Cites] Atherosclerosis. 2008 Jan;196(1):180-9 [17466310.001]
  • [Cites] J Am Coll Cardiol. 2008 Apr 22;51(16):1604-12 [18420105.001]
  • [Cites] Expert Rev Cardiovasc Ther. 2008 Oct;6(9):1203-15 [18939908.001]
  • [Cites] J Urol. 2009 May;181(5):1998-2006; discussion 2007-8 [19286225.001]
  • [Cites] Endocr J. 2009;56(3):317-34 [18753704.001]
  • [Cites] Prostate. 2009 Oct 1;69(14):1493-506 [19536794.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):60-7 [10585584.001]
  • [Cites] J Urol. 2000 Mar;163(3):1027-32 [10688043.001]
  • [Cites] Carcinogenesis. 2001 May;22(5):701-7 [11323387.001]
  • [Cites] J Lipid Res. 2001 Jun;42(6):967-75 [11369805.001]
  • [Cites] J Biol Chem. 2001 Aug 24;276(34):31780-5 [11427538.001]
  • [Cites] Circulation. 2001 Oct 16;104(16):1978-83 [11602504.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):846-52 [12115487.001]
  • [Cites] Mol Cell Biol. 2002 Aug;22(16):5962-74 [12138205.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Sep 6;296(5):1051-7 [12207878.001]
  • [Cites] J Biol Chem. 2003 Mar 14;278(11):9142-9 [12511559.001]
  • [Cites] Lancet. 2003 Mar 8;361(9360):859-64 [12642065.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):712-9 [12615688.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):802-8 [12637339.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):54-69 [14689582.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1515-21 [14973113.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):790-4 [15033469.001]
  • [Cites] Cancer. 1973 Jul;32(1):196-205 [4123791.001]
  • [Cites] Anal Biochem. 1975 May 12;65(1-2):42-9 [165752.001]
  • [Cites] Methods Enzymol. 1986;129:628-44 [3523160.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):598-604 [2743254.001]
  • [Cites] J Natl Cancer Inst. 1993 Oct 6;85(19):1571-9 [8105097.001]
  • [Cites] Science. 1996 Jan 26;271(5248):518-20 [8560269.001]
  • [Cites] J Urol. 2005 Feb;173(2):342-59 [15643172.001]
  • (PMID = 20671065.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / NIH0013975756; United States / PHS HHS / / NIH0013975756; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCA1 protein, human; 0 / ATP Binding Cassette Transporter 1; 0 / ATP-Binding Cassette Transporters; 0 / Androgens; 0 / Lipoproteins, HDL; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 97C5T2UQ7J / Cholesterol; AGG2FN16EV / Simvastatin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS222887; NLM/ PMC2941551
  •  go-up   go-down



27. van de Luijtgaarden AC, Veth RP, Slootweg PJ, Wijers-Koster PM, Schultze Kool LJ, Bovee JV, van der Graaf WT: Metastatic potential of an aneurysmal bone cyst. Virchows Arch; 2009 Nov;455(5):455-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aneurysmal bone cysts (ABCs) are benign bone tumors consisting of blood-filled cavities lined by connective tissue septa.
  • Diagnosis was confirmed by the presence of a break in the USP6 gene, which is pathognomonic for ABC, in a pulmonary metastasis of our patient.
  • Sarcomatous transformation as an explanation for this behavior was ruled out by demonstrating diploid DNA content in both the pulmonary lesion and the primary tumor.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):233-4 [10825009.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):311-5 [16755186.001]
  • [Cites] J Clin Oncol. 2006 Jan 1;24(1):e1; author reply e2 [16382110.001]
  • [Cites] Oncogene. 2005 May 12;24(21):3419-26 [15735689.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Nov;26(3):265-6 [10502326.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1206-10 [11106078.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):583-602 [19396867.001]
  • [Cites] Cancer Genet Cytogenet. 2007 Oct 15;178(2):155-9 [17954273.001]
  • [Cites] Pediatr Dev Pathol. 2007 Jan-Feb;10(1):46-9 [17378626.001]
  • [Cites] Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43 [16808643.001]
  • [Cites] Pediatr Dev Pathol. 2001 Jul-Aug;4(4):418-9 [11441369.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Sep;129(2):177-80 [11566352.001]
  • [Cites] Virchows Arch. 2001 Nov;439(5):636-9 [11764383.001]
  • [Cites] Anal Cell Pathol. 2001;23(2):89-95 [11904464.001]
  • [Cites] Life Sci. 2003 Aug 1;73(11):1427-36 [12850503.001]
  • [Cites] J Formos Med Assoc. 2003 Sep;102(9):631-6 [14625608.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):1920-3 [15026324.001]
  • [Cites] Mod Pathol. 2004 May;17(5):518-25 [15044915.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1773-80 [15509545.001]
  • [Cites] Pediatr Radiol. 1986;16(2):140-3 [3456553.001]
  • [Cites] Skeletal Radiol. 1987;16(3):196-200 [3473690.001]
  • [Cites] Cancer. 1988 Jun 15;61(12):2532-40 [3163257.001]
  • [Cites] Ital J Orthop Traumatol. 1987 Dec;13(4):425-36 [3503870.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Jan;58(1):2-13 [1728946.001]
  • [Cites] Cancer. 1992 Jun 15;69(12):2921-31 [1591685.001]
  • [Cites] Surg Today. 1994;24(5):476-80 [8054822.001]
  • [Cites] Cytometry. 1995 Mar 1;19(3):256-62 [7736870.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Oct 1;84(1):27-31 [7497439.001]
  • [Cites] Pathologe. 1996 Jan;17(1):44-9 [8685095.001]
  • [Cites] Clin Orthop Relat Res. 1997 Feb;(335):253-61 [9020226.001]
  • (PMID = 19838726.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins; 2S9ZZM9Q9V / Bevacizumab; EC 3.1.2.15 / USP6 protein, human; EC 3.1.2.15 / Ubiquitin Thiolesterase
  •  go-up   go-down



28. Schiopu C, Flangea C, Capitan F, Serb A, Vukelić Z, Kalanj-Bognar S, Sisu E, Przybylski M, Zamfir AD: Determination of ganglioside composition and structure in human brain hemangioma by chip-based nanoelectrospray ionization tandem mass spectrometry. Anal Bioanal Chem; 2009 Dec;395(8):2465-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here on a preliminary investigation of ganglioside composition and structure in human hemangioma, a benign tumor in the frontal cortex (HFC) in comparison to normal frontal cortex (NFC) tissue using for the first time advanced mass spectrometric methods based on fully automated chip-nanoelectrospray (nanoESI) high-capacity ion trap (HCT) and collision-induced dissociation (CID).
  • Fragmentation analysis by CID in MS(2) mode using as precursors the ions corresponding to GT1 (d18:1/20:0) and GD1 (d18:1/20:0) provided data corroborating for the first time the presence of the common GT1a and GT1b isomers and the incidence of unusual GT1c and GT1d glycoforms in brain hemangioma tumor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Gangliosides / chemistry. Gangliosides / metabolism. Hemangioma / metabolism. Spectrometry, Mass, Electrospray Ionization / methods. Tandem Mass Spectrometry / methods

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19841910.001).
  • [ISSN] 1618-2650
  • [Journal-full-title] Analytical and bioanalytical chemistry
  • [ISO-abbreviation] Anal Bioanal Chem
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Gangliosides; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down



29. Li X, Placencio V, Iturregui JM, Uwamariya C, Sharif-Afshar AR, Koyama T, Hayward SW, Bhowmick NA: Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene; 2008 Nov 27;27(56):7118-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
  • In mice, the conditional stromal knockout of the TGF-beta type II receptor expression (Tgfbr2(fspKO)) resulted in the development of prostatic intraepithelial neoplasia and progression to adenocarcinoma within 7 months.
  • Clinically, we observed a loss of TGF-beta receptor type II expression in 69% of human prostate cancer-associated stroma, compared to 15% of stroma associated with benign tissues (n=140, P-value <0.0001).

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Jan 1;67(1):75-84 [17210685.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] J Clin Invest. 2007 May;117(5):1305-13 [17415413.001]
  • [Cites] Clin Cancer Res. 2007 Aug 15;13(16):4769-76 [17699854.001]
  • [Cites] Carcinogenesis. 2007 Dec;28(12):2467-75 [17690110.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):1-10 [10696454.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):230-5 [10861498.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2314-29 [10995388.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6008-17 [11085521.001]
  • [Cites] J Cell Physiol. 2001 Feb;186(2):153-68 [11169452.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8135-42 [11719442.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2679-94 [11965541.001]
  • [Cites] J Cell Biochem. 2002;86(4):665-77 [12210733.001]
  • [Cites] Cell. 2003 Jun 13;113(6):685-700 [12809600.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8621-3 [12861075.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):491-8 [14760070.001]
  • [Cites] Science. 2004 Feb 6;303(5659):848-51 [14764882.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1345-56 [15316903.001]
  • [Cites] Development. 2004 Oct;131(20):4955-64 [15371309.001]
  • [Cites] J Urol. 1982 Oct;128(4):858-61 [7143620.001]
  • [Cites] Cell. 1982 Nov;31(1):99-109 [6297757.001]
  • [Cites] Nature. 1984 Jan 12-18;307(5947):131-6 [6318122.001]
  • [Cites] Endocrinology. 1990 Mar;126(3):1343-54 [2307108.001]
  • [Cites] In Vitro Cell Dev Biol. 1990 Jul;26(7):722-30 [2384450.001]
  • [Cites] Cell. 1991 Jan 25;64(2):231 [1846319.001]
  • [Cites] Acta Anat (Basel). 1992;143(2):139-50 [1598820.001]
  • [Cites] J Cell Sci. 1992 Jun;102 ( Pt 2):361-72 [1400638.001]
  • [Cites] Cancer. 1994 Aug 1;74(3 Suppl):1030-44 [8039137.001]
  • [Cites] Carcinogenesis. 1995 Jul;16(7):1499-503 [7614683.001]
  • [Cites] J Urol. 1995 Oct;154(4):1295-9 [7544835.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5408-14 [7585610.001]
  • [Cites] J Histochem Cytochem. 1998 Mar;46(3):379-88 [9487120.001]
  • [Cites] Cancer Res. 1998 Jun 15;58(12):2520-3 [9635571.001]
  • [Cites] Clin Cancer Res. 1998 Jul;4(7):1625-30 [9676836.001]
  • [Cites] J Immunol. 1998 Aug 15;161(4):1772-7 [9712043.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Clin Cancer Res. 1996 Aug;2(8):1255-61 [9816295.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5329-32 [9850059.001]
  • [Cites] Genes Cells. 1998 Oct;3(10):659-70 [9893023.001]
  • [Cites] Mol Cancer. 2007;6:69 [17967179.001]
  • [Cites] Bioessays. 1999 Dec;21(12):1021-30 [10580987.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] J Clin Oncol. 2005 Mar 20;23(9):2078-93 [15774796.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2005;8(2):119-26 [15809669.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5153-62 [15958559.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Oncogene. 2006 May 4;25(19):2773-84 [16407846.001]
  • [Cites] Cancer Lett. 2006 Jun 8;237(1):22-32 [16023783.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Rev Endocr Metab Disord. 2006 Jun;7(1-2):41-9 [16944325.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):320-4 [9927040.001]
  • [Cites] Growth Factors. 1998;16(2):101-10 [9932228.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1366-71 [10096572.001]
  • [Cites] Nature. 2004 Nov 18;432(7015):332-7 [15549095.001]
  • [Cites] Hum Pathol. 2007 Apr;38(4):598-606 [17258791.001]
  • (PMID = 18724388.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA108646; United States / NIGMS NIH HHS / GM / F31 GM079879; United States / PHS HHS / / FGM079879A; United States / NCI NIH HHS / CA / U54 CA126505; United States / NCI NIH HHS / CA / CA126505; United States / NCI NIH HHS / CA / R01 CA108646-04; United States / NCI NIH HHS / CA / T32 CA009592; United States / NCI NIH HHS / CA / R01 CA108646; None / None / / R01 CA108646-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ligands; 0 / Receptors, Transforming Growth Factor beta; 0 / Transforming Growth Factor beta; 0 / WNT3A protein, human; 0 / Wnt Proteins; 0 / Wnt3 Protein; 0 / Wnt3A Protein; 0 / Wnt3a protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  • [Other-IDs] NLM/ NIHMS142310; NLM/ PMC3222150
  •  go-up   go-down



30. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down



31. Chesnokova V, Melmed S: Pituitary senescence: the evolving role of Pttg. Mol Cell Endocrinol; 2010 Sep 15;326(1-2):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the high prevalence of pituitary adenomas they are invariably benign, indicative of unique intrinsic mechanisms controlling pituitary cell proliferation.
  • Cellular senescence is characterized by a largely irreversible cell cycle arrest and constitutes a strong anti-proliferative response, which can be triggered by DNA damage, chromosomal instability and aneuploidy, loss of tumor suppressive signaling or oncogene activation.
  • Here we discuss prospective mechanisms underlying senescence-associated molecular pathways activated in benign pituitary adenomas.
  • Both deletion and over-expression of pituitary tumor transforming gene (Pttg) promote chromosomal instability and aneuploidy.
  • Pttg deletion abrogates tumor development by activating p53/p21-dependent senescence pathways.
  • Pituitary p21 may therefore safeguard against further chromosomal instability by constraining pituitary tumor growth.
  • These observations point to senescence as a target for effective therapy for both tumor silencing and growth restraint towards development of pituitary malignancy.

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1870-9 [11682618.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S27-31 [11684439.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1729-33 [11748253.001]
  • [Cites] Oncogene. 2002 Jan 21;21(4):503-11 [11850775.001]
  • [Cites] Cell. 2002 May 3;109(3):335-46 [12015983.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3428-32 [12626748.001]
  • [Cites] Front Neuroendocrinol. 2003 Apr;24(2):94-127 [12763000.001]
  • [Cites] Endocr Relat Cancer. 2003 Jun;10(2):323-30 [12790793.001]
  • [Cites] Cell. 2003 Jun 13;113(6):703-16 [12809602.001]
  • [Cites] Endocrinology. 2003 Nov;144(11):4991-8 [12960092.001]
  • [Cites] J Clin Invest. 2003 Dec;112(11):1603-18 [14660734.001]
  • [Cites] J Clin Invest. 2004 Jan;113(2):160-8 [14722605.001]
  • [Cites] Nature. 1989 Aug 31;340(6236):692-6 [2549426.001]
  • [Cites] Nature. 1990 May 31;345(6274):458-60 [2342578.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]
  • [Cites] Cell. 1997 Mar 7;88(5):593-602 [9054499.001]
  • [Cites] Mol Endocrinol. 1997 Apr;11(4):433-41 [9092795.001]
  • [Cites] Mol Endocrinol. 1999 Jan;13(1):156-66 [9892021.001]
  • [Cites] Prog Mol Subcell Biol. 1998;20:43-71 [9928526.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1002-7 [9927683.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1317-21 [10546001.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Feb;84(2):761-7 [10022450.001]
  • [Cites] Science. 1999 Jul 16;285(5426):418-22 [10411507.001]
  • [Cites] Exp Cell Res. 1961 Dec;25:585-621 [13905658.001]
  • [Cites] Ann Diagn Pathol. 2005 Feb;9(1):6-10 [15692944.001]
  • [Cites] Mol Endocrinol. 2005 May;19(5):1383-91 [15677710.001]
  • [Cites] Oncogene. 2005 Jul 14;24(30):4861-6 [15897900.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):642 [16079833.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):660-5 [16079837.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):720-4 [16079850.001]
  • [Cites] Science. 2005 Aug 5;309(5736):886-7 [16081723.001]
  • [Cites] Mol Endocrinol. 2005 Sep;19(9):2371-9 [15919720.001]
  • [Cites] Cancer Res. 2005 Oct 1;65(19):8747-53 [16204044.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Oct;27(5):241-52 [16447816.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):707-16 [16954426.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):1037-46 [16957149.001]
  • [Cites] Nature. 2006 Nov 30;444(7119):633-7 [17136093.001]
  • [Cites] Am J Physiol Cell Physiol. 2007 Sep;293(3):C1082-92 [17626243.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10564-72 [17975001.001]
  • [Cites] Endocrinology. 2007 Dec;148(12):6019-25 [17872367.001]
  • [Cites] Cell Death Differ. 2008 Jan;15(1):202-12 [17962814.001]
  • [Cites] Trends Genet. 2008 Feb;24(2):77-85 [18192065.001]
  • [Cites] Science. 2008 Mar 7;319(5868):1352-5 [18323444.001]
  • [Cites] Cell. 2008 Jun 13;133(6):958-61 [18555773.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17498-503 [18981426.001]
  • [Cites] Pituitary. 2009;12(1):40-50 [18270844.001]
  • [Cites] Nat Rev Cancer. 2009 Feb;9(2):81-94 [19132009.001]
  • [Cites] Cell Cycle. 2009 Mar 1;8(5):677-8 [19223763.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Mar;72(3):377-82 [19650784.001]
  • [Cites] Nat Clin Pract Endocrinol Metab. 2006 Dec;2(12):681-93 [17143315.001]
  • [Cites] Nature. 2006 Dec 21;444(7122):1038-43 [17183314.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19842-7 [17170138.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):749-59 [17071631.001]
  • [Cites] Endocr Rev. 2007 Apr;28(2):165-86 [17325339.001]
  • [Cites] Cell. 2007 Jul 27;130(2):223-33 [17662938.001]
  • [Cites] J Biol Chem. 2000 Nov 24;275(47):36502-5 [11013229.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Feb;86(2):867-74 [11158059.001]
  • (PMID = 20153804.001).
  • [ISSN] 1872-8057
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075979-11A1; United States / NCI NIH HHS / CA / R01 CA075979; United States / NCI NIH HHS / CA / R01 CA075979-11A1
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  • [Other-IDs] NLM/ NIHMS185500; NLM/ PMC2906651
  •  go-up   go-down



32. Satsuka A, Sakai H: [Life cycle of HPV governed by the differentiation program of epithelial cell]. Uirusu; 2008 Dec;58(2):165-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Papillomavirus is a pathogenic virus that induces benign tumor at the infected lesion, and its association with malignant tumor was first identified by R.
  • Because of its clinical importance, the study on HPV has been focused on the oncogenic properties, and the results of which had great impacts on the researches of the tumor suppressors, such as p53 and pRb, and "ubiquiitn-proteasome" pathway.
  • [MeSH-minor] Animals. Gene Expression Regulation, Viral. Gene Silencing. Genes, Tumor Suppressor. Genome, Viral. Humans. Open Reading Frames / genetics. Virus Replication / genetics

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19374194.001).
  • [ISSN] 0042-6857
  • [Journal-full-title] Uirusu
  • [ISO-abbreviation] Uirusu
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 33
  •  go-up   go-down



33. Zhu X, Ma LL, Ye T: Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance. J Clin Lab Anal; 2009;23(4):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To evaluate the expressions of CD4(+)CD25(high)CD127(low/-) regulatory T cells (Tregs) in peripheral blood from patients with transitional cell carcinoma (TCC) in urinary system, we investigated the proportion of Treg population in CD4(+) T from 93 patients with TCC, 38 with benign urinary diseases, and 37 healthy subjects by using flow cytometric analysis and analyzing different clinicopathologic characteristics and the changes before and after operation.
  • There was a strong correlation between the proportion of Treg and tumor recurrence, quantity, lymph node metastasis (P<0.01), as well as pathological stage; no correlation was found between the proportion of Treg and clinical TNM stage (P>0.05).
  • The resection of tumor can decrease the proportion of Treg in peripheral blood.
  • [MeSH-major] Antigens, CD / immunology. Biomarkers, Tumor / blood. Carcinoma, Transitional Cell / immunology. T-Lymphocytes, Regulatory / immunology. Urologic Neoplasms / immunology

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19623656.001).
  • [ISSN] 1098-2825
  • [Journal-full-title] Journal of clinical laboratory analysis
  • [ISO-abbreviation] J. Clin. Lab. Anal.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Biomarkers, Tumor; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Interleukin-7 Receptor alpha Subunit
  •  go-up   go-down



34. Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J: Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med; 2008 Sep;60(3):510-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A long-echo-time rotor-synchronized Carr-Purcell-Meiboom-Gill (CPMG) sequence including an electronic reference to access in vivo concentrations (ERETIC) standard was used to determine the concentrations of lactate and alanine in 82 benign and 16 malignant biopsies (mean 26.5% +/- 17.2% of core).
  • Low concentrations of lactate (0.61 +/- 0.28 mmol/kg) and alanine (0.14 +/- 0.06 mmol/kg) were observed in benign prostate biopsies, and there was no significant difference between benign predominantly glandular (N = 54) and stromal (N = 28) biopsies between patients with (N = 38) and without (N = 44) a positive clinical biopsy.
  • In biopsies containing prostate cancer there was a highly significant (P < 0.0001) increase in lactate (1.59 +/- 0.61 mmol/kg) and alanine (0.26 +/- 0.07 mmol/kg), and minimal overlap with lactate concentrations in benign biopsies.
  • This study demonstrates for the first time very low concentrations of lactate and alanine in benign prostate biopsy tissues.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. (L)-ALANINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 2006 Aug;68(2):244-8 [16904427.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):739-49 [16954428.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10855-60 [17108122.001]
  • [Cites] Radiology. 2007 Apr;243(1):28-53 [17392247.001]
  • [Cites] Abdom Imaging. 2007 Mar-Apr;32(2):253-61 [17476554.001]
  • [Cites] Magn Reson Med. 2007 Jul;58(1):65-9 [17659629.001]
  • [Cites] Magn Reson Med. 2007 Dec;58(6):1099-106 [17969006.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):95-102 [16890323.001]
  • [Cites] Radiology. 1999 Nov;213(2):473-80 [10551229.001]
  • [Cites] J Radiol. 2004 Dec;85(12 Pt 1):1999-2004 [15692410.001]
  • [Cites] Radiology. 2005 Mar;234(3):804-14 [15734935.001]
  • [Cites] Clin Exp Metastasis. 2005;22(1):25-30 [16132575.001]
  • [Cites] Solid State Nucl Magn Reson. 2006 Feb;29(1-3):214-8 [16229992.001]
  • [Cites] Radiology. 2006 Feb;238(2):597-603 [16344335.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):523-30 [16471314.001]
  • [Cites] Mol Cell Biochem. 2005 Dec;280(1-2):1-8 [16511951.001]
  • [Cites] Curr Opin Oncol. 2006 May;18(3):284-8 [16552242.001]
  • [Cites] J Invest Dermatol. 2006 Jun;126(6):1378-87 [16543892.001]
  • [Cites] Magn Reson Med. 2006 Jun;55(6):1257-64 [16685733.001]
  • [Cites] Radiology. 1999 Nov;213(2):481-8 [10551230.001]
  • [Cites] Radiol Clin North Am. 2000 Jan;38(1):115-38, viii-ix [10664669.001]
  • [Cites] J Urol. 2000 Aug;164(2):400-4 [10893595.001]
  • [Cites] FEBS Lett. 2001 Apr 6;494(1-2):112-6 [11297745.001]
  • [Cites] Magn Reson Med. 2001 Jul;46(1):49-57 [11443710.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):349-53 [11567808.001]
  • [Cites] Radiology. 2001 Nov;221(2):380-90 [11687679.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Jun;129(6):321-6 [12827509.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10158-63 [12930897.001]
  • [Cites] Magn Reson Med. 2003 Nov;50(5):944-54 [14587005.001]
  • [Cites] Anticancer Res. 2003 Sep-Oct;23(5b):4223-7 [14666629.001]
  • [Cites] Magn Reson Med. 2004 Jul;52(1):147-53 [15236378.001]
  • [Cites] Curr Med Chem. 2004 Aug;11(16):2195-204 [15279558.001]
  • [Cites] J Biol Chem. 1984 May 25;259(10):6215-21 [6144677.001]
  • [Cites] Magn Reson Med. 1991 Jun;19(2):429-38 [1715505.001]
  • [Cites] Magn Reson Med. 1993 Mar;29(3):285-91 [7680746.001]
  • [Cites] J Urol. 1993 Dec;150(6):2019-24 [7693985.001]
  • [Cites] Prostate. 1994 Sep;25(3):162-6 [7520580.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):4757-9 [7585499.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):399-404 [9299252.001]
  • [Cites] NMR Biomed. 1997 Dec;10(8):411-22 [9542738.001]
  • [Cites] J Magn Reson. 1998 Aug;133(2):243-54 [9716465.001]
  • [Cites] Radiology. 2004 Nov;233(2):441-8 [15375223.001]
  • [Cites] Magn Reson Med. 2005 Jan;53(1):41-8 [15690501.001]
  • (PMID = 18727052.001).
  • [ISSN] 1522-2594
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / R21 EB005363-03; United States / NCI NIH HHS / CA / K01 CA96618; United States / NCI NIH HHS / CA / K01 CA096618-04; United States / NCI NIH HHS / CA / R01 CA102751; United States / NIBIB NIH HHS / EB / R21 EB05363; United States / NCI NIH HHS / CA / CA096618-04; United States / NIBIB NIH HHS / EB / EB005363-03; United States / NIBIB NIH HHS / EB / R21 EB005363; United States / NCI NIH HHS / CA / K01 CA096618
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Lactates; OF5P57N2ZX / Alanine
  • [Other-IDs] NLM/ NIHMS83785; NLM/ PMC2613807
  •  go-up   go-down



35. Iqbal J, Liu T, Mapow B, Swami VK, Hou JS: Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies. Anal Quant Cytol Histol; 2010 Jun;32(3):161-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of flow cytometric analysis of serous effusions in the diagnosis of hematopoietic neoplasms in patients with prior hematopoietic malignancies.
  • OBJECTIVE: To determine the criteria for the use of immunophenotyping by flow cytometry (FCM) in the diagnosis of hematopoietic lesions.
  • The cytopathologic diagnosis was compared with the final diagnosis as modified by subsequent FCM.
  • RESULTS: The cytopathologic diagnosis was benign in 61 cases (69%), atypical in 20 cases (22%) and malignant in 8 cases (9%).
  • In these patients, the working cytopathologic diagnosis was modified from benign/atypical to malignant in 2 (11%) cases and atypical to benign in 11 (33%) cases.
  • CONCLUSION: FCM studies were helpful in the cytopathologic diagnosis in 35% of body fluid specimens, permitting appropriate cancer staging and management.
  • In the absence of a prior clinical history, immunophenotyping by FCM in body fluid specimens should be ordered after adequacy studies when there is cytologic atypia or a strong suspicion of malignancy on the cytopathologic diagnosis.

  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20701070.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down



36. Ranaldi R, Morichetti D, Goteri G, Martino A: Immature teratoma of the mediastinum arising in ectopic thyroid tissue: a case report. Anal Quant Cytol Histol; 2009 Aug;31(4):233-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histologic examination revealed the presence of a discontinuous rim of compressed thyroid follicles on the outer aspect of the tumor capsule.
  • The patient was free of disease after 22 months, in accordance with the benign behavior of immature teratoma in infancy.

  • Genetic Alliance. consumer health - Teratoma.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19736871.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 9010-34-8 / Thyroglobulin
  •  go-up   go-down



37. McLerran D, Grizzle WE, Feng Z, Bigbee WL, Banez LL, Cazares LH, Chan DW, Diaz J, Izbicka E, Kagan J, Malehorn DE, Malik G, Oelschlager D, Partin A, Randolph T, Rosenzweig N, Srivastava S, Srivastava S, Thompson IM, Thornquist M, Troyer D, Yasui Y, Zhang Z, Zhu L, Semmes OJ: Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem; 2008 Jan;54(1):44-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias.
  • METHODS: We derived the decision algorithm used in this study from the analysis of serum samples from patients with prostate cancer (n = 181) and benign prostatic hyperplasia (BPH) (n = 143) and normal controls (n = 220).

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Biospecimen Research Database. Biospecimen Research Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1576-8 [12381711.001]
  • [Cites] Clin Breast Cancer. 2003 Aug;4(3):203-9 [14499014.001]
  • [Cites] BMC Bioinformatics. 2003 Jun 9;4:24 [12795817.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):353-6 [14996856.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2239-46 [15163773.001]
  • [Cites] Dis Markers. 2003-2004;19(4-5):185-95 [15258333.001]
  • [Cites] Clin Chem. 2004 Dec;50(12):2398-401 [15563493.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Nat Rev Cancer. 2005 Feb;5(2):142-9 [15685197.001]
  • [Cites] Clin Chem. 2005 Aug;51(8):1525-8 [15951319.001]
  • [Cites] Clin Chem. 2005 Sep;51(9):1637-49 [16002455.001]
  • [Cites] Proteomics. 2006 Mar;6(5):1676-80 [16447157.001]
  • [Cites] Clin Chem. 2006 Apr;52(4):771-2; author reply 772 [16595832.001]
  • [Cites] Proteomics. 2006 May;6(10):3189-98 [16586434.001]
  • [Cites] Clin Chem. 2006 Jul;52(7):1218-22 [16675505.001]
  • [Cites] Biometrics. 2006 Jun;62(2):589-97 [16918924.001]
  • [Cites] J Proteome Res. 2006 Sep;5(9):2079-82 [16944917.001]
  • [Cites] Nat Clin Pract Rheumatol. 2007 Feb;3(2):96-103 [17299447.001]
  • [Cites] Clin Chem. 2007 Apr;53(4):645-56 [17303688.001]
  • [Cites] Anal Chem. 2005 Aug 15;77(16):5114-23 [16097747.001]
  • [Cites] Proteomics. 2005 Aug;5(13):3262-77 [16052621.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1491-502 [11290567.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1868-75 [11912167.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3609-14 [12097261.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1835-43 [12324514.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):3-5 [18160722.001]
  • [CommentIn] Clin Chem. 2008 Jan;54(1):6-7 [18160723.001]
  • (PMID = 17981926.001).
  • [ISSN] 0009-9147
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 084986; United States / NCI NIH HHS / CA / CA 84968; United States / NCI NIH HHS / CA / P50 CA058236; United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CA / CA 86368; United States / NCI NIH HHS / CA / U01 CA086402; United States / NCI NIH HHS / CA / U01 CA085067; United States / NCI NIH HHS / CA / U01 CA086323; United States / NCI NIH HHS / CA / U24 CA086368; United States / NCI NIH HHS / CA / U01 CA086368; United States / NCI NIH HHS / CA / CA 86359; United States / NCI NIH HHS / CA / CA 86402; United States / NCI NIH HHS / CA / U24 CA086359; United States / NCI NIH HHS / CA / CA 86323; United States / NCI NIH HHS / CA / U01 CA084968; United States / NCI NIH HHS / CA / CA 85067; United States / NCI NIH HHS / CA / U01 CA084986
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS371877; NLM/ PMC3354530
  •  go-up   go-down



38. Hilfrich R, Hariri J: Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol; 2008 Apr;30(2):78-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifty sections were derived from a benign group, 91 from low-grade (cervical intraepithelial neoplasia [CIN 1]) lesions and 50 from high-grade (CIN 2 and 3) lesions.



39. Garrison JB, Kyprianou N: Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. Cancer Res; 2006 Jan 1;66(1):464-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway.
  • In this study, the molecular events initiating this apoptotic effect were further investigated in vitro using the human androgen-independent prostate cancer cells PC-3 and the human benign prostate epithelial cells BPH-1.
  • These results show that doxazosin exerts its apoptotic effects against benign and malignant prostate cells via a death receptor-mediated mechanism with a potential integrin contribution towards cell survival outcomes.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Annu Rev Cell Dev Biol. 1999;15:269-90 [10611963.001]
  • [Cites] Cell Death Differ. 2005 Mar;12(3):233-42 [15665818.001]
  • [Cites] Cell Tissue Res. 2000 Jul;301(1):153-62 [10928288.001]
  • [Cites] J Cell Biol. 2001 Feb 5;152(3):633-43 [11157988.001]
  • [Cites] J Urol. 2003 Mar;169(3):1150-6 [12576871.001]
  • [Cites] J Urol. 2003 Apr;169(4):1520-5 [12629407.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):593-600 [12740905.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2795-804 [12743602.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1615-21 [12771931.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):386-93 [12811833.001]
  • [Cites] J Biol Chem. 2003 Sep 26;278(39):37632-6 [12876280.001]
  • [Cites] J Med Chem. 2004 Aug 26;47(18):4453-62 [15317457.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] Cell. 1995 May 19;81(4):505-12 [7538907.001]
  • [Cites] Cell. 1996 Jun 14;85(6):817-27 [8681377.001]
  • [Cites] Nat Med. 1996 Dec;2(12):1361-6 [8946836.001]
  • [Cites] Curr Biol. 1996 Oct 1;6(10):1241-3 [8939562.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 4;89(11):783-9 [9182976.001]
  • [Cites] Cell Immunol. 1997 Aug 25;180(1):70-83 [9316641.001]
  • [Cites] Br J Urol. 1997 Oct;80(4):521-32 [9352686.001]
  • [Cites] Cancer Res. 1998 Jan 1;58(1):76-83 [9426061.001]
  • [Cites] Prostate. 1998 Jul 1;36(2):92-101 [9655261.001]
  • [Cites] Cancer Res. 1998 Dec 15;58(24):5870-5 [9865748.001]
  • [Cites] Clin Cancer Res. 1997 Jun;3(6):963-72 [9815772.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):382-90 [9927051.001]
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7987-92 [10075697.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Mar 24;256(3):603-7 [10080945.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5205-11 [10227994.001]
  • [Cites] Cell Death Differ. 1999 May;6(5):394-401 [10381629.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):371-8 [10408840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704 [10411938.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1043-6 [10508619.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1047-9 [10508612.001]
  • [Cites] Oncogene. 2001 Apr 5;20(15):1852-9 [11313933.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):319-27 [11803475.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):597-602 [11809715.001]
  • [Cites] Prostate. 2002 Apr 1;51(1):42-9 [11920957.001]
  • [Cites] Apoptosis. 2002 Jun;7(3):247-60 [11997669.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):231-40 [11987151.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):296-300 [12124829.001]
  • [Cites] Anal Quant Cytol Histol. 2000 Feb;22(1):45-54 [10696460.001]
  • (PMID = 16397262.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107575; United States / NCI NIH HHS / CA / R01 CA107575-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Adrenergic alpha-Antagonists; 0 / Antigens, CD95; 0 / FADD protein, human; 0 / Fas-Associated Death Domain Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases; NW1291F1W8 / Doxazosin
  • [Other-IDs] NLM/ NIHMS19062; NLM/ PMC1850148
  •  go-up   go-down



40. Leelawat K, Sakchinabut S, Narong S, Wannaprasert J: Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol; 2009;9:30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cholangiocarcinoma is an aggressive tumor with a tendency for local invasion and distant metastases.
  • Timely diagnosis is very important because surgical resection (R0) remains the only hope for a cure.
  • However, at present, there is no available tumor marker that can differentiate cholangiocarcinoma from benign bile duct disease.
  • METHODS: This study was designed to determine whether the serum levels of MMP-7 and MMP-9 can discriminate cholangiocarcinoma patients from benign biliary tract disease patients in comparison to carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9).
  • We measured the level of CEA, CA19-9, MMP-7 and MMP-9 in the serum of 44 cholangiocarcinoma and 36 benign biliary tract diseases patients.
  • RESULTS: Among the serum levels of CEA, CA19-9, MMP-7 and MMP-9, only the serum MMP-7 level was significantly higher in the patients with cholangiocarcinoma (8.9 +/- 3.43 ng/ml) compared to benign biliary tract disease patients (5.9 +/- 3.03 ng/ml) (p < 0.001).
  • An receiver operating characteristic (ROC) curve analysis revealed that the detection of the serum MMP-7 level is reasonably accurate in differentiating cholangiocarcinoma from benign biliary tract disease patients (area under curve = 0.73; 95% CI = 0.614-0.848).
  • CONCLUSION: Serum MMP-7 appears to be a valuable diagnostic marker in the discrimination of cholangiocarcinoma from benign biliary tract disease.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic. Biliary Tract Diseases / diagnosis. Biomarkers, Tumor / blood. Cholangiocarcinoma / diagnosis. Matrix Metalloproteinase 7 / blood. Matrix Metalloproteinase 9 / blood
  • [MeSH-minor] Adult. Aged. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Diagnosis, Differential. Female. Humans. Jaundice, Obstructive / blood. Jaundice, Obstructive / diagnosis. Male. Middle Aged. ROC Curve. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Chem. 2008 Mar;54(3):574-81 [18202161.001]
  • [Cites] Clin Liver Dis. 2008 Feb;12(1):131-50, ix [18242501.001]
  • [Cites] Curr Opin Gastroenterol. 2008 May;24(3):349-56 [18408464.001]
  • [Cites] Hum Pathol. 2008 May;39(5):710-9 [18329694.001]
  • [Cites] Can J Gastroenterol. 2008 Aug;22(8):689-98 [18701947.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] Dig Dis Sci. 2008 Dec;53(12):3213-7 [18465243.001]
  • [Cites] World J Surg. 2008 Dec;32(12):2675-80 [18843437.001]
  • [Cites] J Hepatol. 2009 Jan;50(1):158-64 [19012991.001]
  • [Cites] Dig Dis Sci. 2009 Jun;54(6):1203-7 [18719998.001]
  • [Cites] Am J Gastroenterol. 2000 Jan;95(1):204-7 [10638584.001]
  • [Cites] Mol Med Today. 2000 Apr;6(4):149-56 [10740253.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1259-62 [14571713.001]
  • [Cites] Anal Biochem. 2003 Nov 15;322(2):283-6 [14596841.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):68-75 [14687144.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):139-54 [15192787.001]
  • [Cites] Int J Dev Biol. 2004;48(5-6):411-24 [15349816.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Ann N Y Acad Sci. 1999 Jun 30;878:212-27 [10415733.001]
  • [Cites] Korean J Gastroenterol. 2005 Jan;45(1):52-9 [15665568.001]
  • [Cites] Transplantation. 2005 Mar 27;79(6):745-6 [15785393.001]
  • [Cites] Tumori. 2006 Mar-Apr;92(2):149-54 [16724695.001]
  • [Cites] Dig Surg. 2006;23(5-6):319-24 [17170527.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1066-71 [17487834.001]
  • [Cites] PLoS Med. 2007 Jul;4(7):e201 [17622191.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1591-5 [17708308.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1174-84 [17919228.001]
  • [Cites] Clin Chim Acta. 2008 Mar;389(1-2):61-6 [18155162.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • (PMID = 19405942.001).
  • [ISSN] 1471-230X
  • [Journal-full-title] BMC gastroenterology
  • [ISO-abbreviation] BMC Gastroenterol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2680894
  •  go-up   go-down



41. Karanikolas BD, Figueiredo ML, Wu L: Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res; 2009 Sep;7(9):1456-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line.
  • Although this correlation means EZH2 could prove valuable as a biomarker in clinical settings, the question remains whether EZH2 is actually responsible for the initiation of these more aggressive tumor types.
  • In this study, EZH2-mediated neoplastic transformation of the normal prostate epithelial cell line benign prostate hyperplasia 1 (BPH1) was confirmed by in vivo tumor growth and in vitro colony formation.

  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Matrix Biol. 1999 Oct;18(5):455-67 [10601733.001]
  • [Cites] BJU Int. 2000 May;85(7):932-44 [10792179.001]
  • [Cites] Genes Dev. 2001 Feb 1;15(3):267-85 [11159908.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):551-7 [11208850.001]
  • [Cites] Curr Opin Genet Dev. 2001 Apr;11(2):175-81 [11250141.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):950-8 [11298590.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8143-9 [11719443.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):2830-5 [11880635.001]
  • [Cites] Nature. 2002 Oct 10;419(6907):624-9 [12374981.001]
  • [Cites] Cell. 2002 Oct 18;111(2):197-208 [12408864.001]
  • [Cites] Science. 2002 Nov 1;298(5595):1039-43 [12351676.001]
  • [Cites] Differentiation. 2002 Dec;70(9-10):473-85 [12492490.001]
  • [Cites] Cell. 2003 Mar 7;112(5):599-606 [12628181.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1981-9 [12702592.001]
  • [Cites] J Natl Cancer Inst. 2003 May 7;95(9):661-8 [12734317.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):459-65 [12778136.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7841-6 [12799464.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2728-43 [12857860.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11 [14500907.001]
  • [Cites] EMBO J. 2003 Oct 15;22(20):5323-35 [14532106.001]
  • [Cites] J Cell Biochem. 2004 Jan 1;91(1):13-25 [14689577.001]
  • [Cites] Neoplasia. 2003 Nov-Dec;5(6):481-8 [14965441.001]
  • [Cites] Curr Opin Genet Dev. 2004 Apr;14(2):155-64 [15196462.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4930-7 [15077161.001]
  • [Cites] Mol Cell. 2004 Jul 2;15(1):57-67 [15225548.001]
  • [Cites] Genes Dev. 2004 Jul 1;18(13):1592-605 [15231737.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5759-69 [15208672.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;24(3):148-54 [2544306.001]
  • [Cites] Cancer Res. 1989 Sep 1;49(17):4682-9 [2547513.001]
  • [Cites] Mol Cell Biol. 1994 Mar;14(3):1721-32 [7906858.001]
  • [Cites] Nucleic Acids Res. 1995 Feb 25;23(4):628-33 [7899083.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 1995 Jan;31(1):14-24 [7535634.001]
  • [Cites] EMBO J. 1997 Jun 2;16(11):3219-32 [9214638.001]
  • [Cites] Mol Cell Biol. 1998 Jun;18(6):3586-95 [9584199.001]
  • [Cites] J Virol. 1998 Oct;72(10):8150-7 [9733856.001]
  • [Cites] J Virol. 1998 Nov;72(11):8463-71 [9765382.001]
  • [Cites] Anal Biochem. 1999 May 15;270(1):41-9 [10328763.001]
  • [Cites] Exp Gerontol. 1999 Apr;34(2):275-87 [10363793.001]
  • [Cites] J Biol Chem. 2005 Jan 14;280(2):1199-208 [15536069.001]
  • [Cites] DNA Cell Biol. 2005 Feb;24(2):117-25 [15699631.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 10;102(19):6942-7 [15860580.001]
  • [Cites] J Biol Chem. 2005 Jun 10;280(23):22437-44 [15817459.001]
  • [Cites] Oncogene. 2005 Sep 15;24(41):6269-80 [16007202.001]
  • [Cites] Science. 2005 Oct 14;310(5746):306-10 [16224021.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7465-74 [16288293.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):268-73 [16330673.001]
  • [Cites] Clin Cancer Res. 2006 Feb 15;12(4):1168-74 [16489070.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):639-45 [16575874.001]
  • [Cites] Methods Enzymol. 2006;407:660-76 [16757360.001]
  • [Cites] J Biol Chem. 2006 Aug 25;281(34):24790-802 [16766534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14122-7 [16959882.001]
  • [Cites] J Cell Physiol. 2007 Jan;210(1):183-91 [16998811.001]
  • [Cites] Genes Dev. 2007 Jan 1;21(1):49-54 [17210787.001]
  • [Cites] Nat Cell Biol. 2007 Mar;9(3):347-53 [17277772.001]
  • [Cites] Prostate. 2007 Apr 1;67(5):547-56 [17252556.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1261-74 [17604717.001]
  • [Cites] Mol Carcinog. 2008 Jun;47(6):466-77 [18058808.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7828-37 [18829538.001]
  • [Cites] Science. 2008 Dec 12;322(5908):1695-9 [19008416.001]
  • [Cites] J Cutan Pathol. 2007 Aug;34(8):597-600 [17640228.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2153-61 [17583576.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):419-31 [17996646.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10657-63 [18006806.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):595-602 [17943722.001]
  • [Cites] Prostate. 2008 Feb 15;68(3):255-63 [18095286.001]
  • [Cites] Dis Markers. 2008;24(3):157-65 [18334737.001]
  • (PMID = 19723877.001).
  • [ISSN] 1557-3125
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA092131-08; United States / NCI NIH HHS / CA / P50 CA092131; United States / NCI NIH HHS / CA / P30 CA016042; United States / NIAID NIH HHS / AI / P30 AI028697; United States / NCI NIH HHS / CA / R01 CA101904-07; United States / NCI NIH HHS / CA / R01 CA101904; United States / NCI NIH HHS / CA / CA101904-07
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Transcription Factors; 147336-22-9 / Green Fluorescent Proteins; EC 2.1.1.- / Protein Methyltransferases; EC 2.1.1.43 / EZH2 protein, human; EC 2.1.1.43 / Polycomb Repressive Complex 2; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ NIHMS159142; NLM/ PMC2794652
  •  go-up   go-down



42. Herrera Espiñeira C, Fernández Valdivia J, López-Cuervo JE, Martínez Tapias J: Textural analysis in the diagnosis of benign and malignant breast cells. Anal Quant Cytol Histol; 2007 Dec;29(6):365-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Textural analysis in the diagnosis of benign and malignant breast cells.
  • OBJECTIVE: To study the discriminatory capacity of textural variables to classify the nuclei of breast tumor cells as benign or malignant, using a statistical approach.
  • The sample comprised 95 cases of malignant lesions and 47 cases of benign lesions (approximately 25 nuclei per case), and 27 textural variables were measured.
  • RESULTS: The variance in gray levels was the most decisive variable in the CART analysis, correctly classifying 57% and 97% of benign and malignant cases, respectively.
  • Discriminant analysis yielded the best results, correctly classifying 79% and 85% of benign and malignant cases, respectively.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225392.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down



43. Koebrugge B, Bosscha K, Ernst MF: Transanal endoscopic microsurgery for local excision of rectal lesions: is there a learning curve? Dig Surg; 2009;26(5):372-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for the local resection of benign and stage T1 rectal lesions in selected patients, associated with lower morbidity and mortality rates than open surgery.
  • Median distance of the lesion from the anal verge was 7.0 cm; median operating time was 90 min.
  • Postoperative staging revealed 77 tubulovillous adenomas, 22 stage T1, 5 stage T2 and 1 stage T3 carcinomas; tumor resection was radical in 86%.
  • TEM remains the treatment of choice for benign lesions and stage T1 rectal carcinomas in selected patients.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 S. Karger AG, Basel.
  • (PMID = 19923824.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down



44. Shantaram M, Rao A, Aroor AR, Raja A, Rao S, Monteiro F: Assessment of total sialic acid and lipid-bound sialic acid in management of brain tumors. Ann Indian Acad Neurol; 2009 Jul;12(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glycoconjugate molecules expressed at the plasma membrane of mammalian cells have been reported to be associated with tumor progression.
  • The measurement of total sialic acid (TSA) and lipid-bound sialic acid (LBSA) in the cerebrospinal fluid (CSF) is suggested to be useful for the diagnosis of brain tumors.
  • OBJECTIVE: The objective of this study is to check the feasibility of using serum glycoconjugates such as TSA and LBSA as tumor markers in brain tumor patients.
  • The LBSA fraction was isolated from the serum of 68 brain tumor patients and evaluated using phosphotungstic acid and resorcinol; follow-up study was done on 23 patients.
  • DISCUSSION: TSA and LBSA do not have the ability to discriminate between benign and malignant brain tumors.
  • TSA and LBSA appear to be tumor markers of very limited value in patients with brain tumors.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Urol Nephrol. 1992;24(2):125-9 [1624255.001]
  • [Cites] Cancer Lett. 1991 Jun 14;58(1-2):91-100 [2049789.001]
  • [Cites] J Oral Maxillofac Surg. 1991 Aug;49(8):843-7 [2072195.001]
  • [Cites] Dis Colon Rectum. 1990 Feb;33(2):139-42 [2298100.001]
  • [Cites] Adv Cancer Res. 1989;52:257-331 [2662714.001]
  • [Cites] Bull Soc Sci Med Grand Duche Luxemb. 1989 Mar-Apr;126(1):17-20 [2663215.001]
  • [Cites] Thyroid. 2005 Jul;15(7):645-52 [16053379.001]
  • [Cites] Clin Biochem. 2005 Jun;38(6):535-9 [15885233.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):912-7 [10841826.001]
  • [Cites] Res Commun Chem Pathol Pharmacol. 1980 Oct;30(1):171-80 [7433766.001]
  • [Cites] Cancer. 1982 Nov 1;50(9):1815-9 [7116306.001]
  • [Cites] Clin Biochem. 1980 Oct;13(5):191-7 [7006855.001]
  • [Cites] Anticancer Res. 1984 Jul-Oct;4(4-5):313-6 [6486735.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1389-94 [3948121.001]
  • [Cites] Int J Biol Markers. 1988 Oct-Dec;3(4):243-8 [3235852.001]
  • [Cites] Clin Chim Acta. 1988 Sep 15;176(3):251-7 [3180477.001]
  • [Cites] Neurol Res. 1986 Jun;8(2):123-6 [2875407.001]
  • [Cites] Obstet Gynecol. 1988 Jan;71(1):20-6 [2827081.001]
  • [Cites] Biochim Biophys Acta. 2008 Mar;1780(3):421-33 [17991443.001]
  • (PMID = 20174496.001).
  • [ISSN] 1998-3549
  • [Journal-full-title] Annals of Indian Academy of Neurology
  • [ISO-abbreviation] Ann Indian Acad Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2824932
  • [Keywords] NOTNLM ; Brain tumors / lipid-bound sialic acid / total sialic acid / tumor markers
  •  go-up   go-down



45. Nese N, Kandiloglu AR, Simsek G, Lekili M, Ozdamar A, Catalkaya A, Coskun T: Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal Quant Cytol Histol; 2010 Apr;32(2):90-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: HSP47 and fascin were localized to cytoplasm, and HSP47 and fascin IR were higher in IDC and PCa than benign groups (p < 0.05).
  • Fascin expression correlated with estrogen receptor and progesterone receptor negativity, tumor size and stage in IDC and surgical margin status in PCa.
  • Although there is no relationship with recurrence or metastatic status, fascin overexpression correlated with tumor size, which may prompt its use as a prognostic factor in IDC.



46. Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res; 2008 Jun 1;14(11):3327-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of genes differentially expressed in benign versus malignant thyroid tumors.
  • PURPOSE: Although fine-needle aspiration biopsy is the most useful diagnostic tool in evaluating a thyroid nodule, preoperative diagnosis of thyroid nodules is frequently imprecise, with up to 30% of fine-needle aspiration biopsy cytology samples reported as "suspicious" or "indeterminate."
  • EXPERIMENTAL DESIGN: In an attempt to identify diagnostic markers for the preoperative distinction of these lesions, we chose to study by microarray analysis the eight different thyroid tumor subtypes that can present a diagnostic challenge to the clinician.
  • RESULTS: Our microarray-based analysis of 94 thyroid tumors identified 75 genes that are differentially expressed between benign and malignant tumor subtypes.
  • Of these, 33 were overexpressed and 42 were underexpressed in malignant compared with benign thyroid tumors.
  • CONCLUSIONS: Our results suggest that these 12 genes could be useful in the development of a panel of markers to differentiate benign from malignant tumors and thus serve as an important first step in solving the clinical problem associated with suspicious thyroid lesions.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Diseases.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thyroid. 1998 May;8(5):377-83 [9623727.001]
  • [Cites] Genes Chromosomes Cancer. 2008 Jan;47(1):56-63 [17943974.001]
  • [Cites] Semin Cancer Biol. 1999 Aug;9(4):303-18 [10448117.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7637-44 [15569996.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1587-97 [15735049.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1693-9 [15753364.001]
  • [Cites] Anal Quant Cytol Histol. 2005 Apr;27(2):101-10 [15913203.001]
  • [Cites] Biochem J. 2005 Jul 1;389(Pt 1):91-7 [15713121.001]
  • [Cites] Methods Mol Med. 2005;103:89-101 [15542899.001]
  • [Cites] Expert Opin Biol Ther. 2005 Aug;5(8):1069-83 [16050784.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] J Pathol. 2006 Jun;209(2):206-12 [16521118.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4773-83 [16899629.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Dec;31(12):1363-6 [10641790.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):595-605 [10666389.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1123-30 [10735494.001]
  • [Cites] Int J Oncol. 2001 Mar;18(3):521-6 [11179481.001]
  • [Cites] Matrix Biol. 2001 Jan;19(8):816-27 [11223341.001]
  • [Cites] Thyroid. 2001 Mar;11(3):271-7 [11327619.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15044-9 [11752453.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):151-63 [11896570.001]
  • [Cites] Cell Calcium. 2002 Jul;32(1):1-10 [12127057.001]
  • [Cites] J Comput Biol. 2002;9(3):505-11 [12162889.001]
  • [Cites] Cancer Res. 2002 Sep 15;62(18):5351-7 [12235006.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]
  • [Cites] Histopathology. 2002 Oct;41(4):357-62 [12383219.001]
  • [Cites] J Pathol. 2003 Feb;199(2):176-84 [12533830.001]
  • [Cites] Pathol Oncol Res. 2002;8(4):231-40 [12579208.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1710-20 [12738725.001]
  • [Cites] Clin Cancer Res. 2003 May;9(5):1792-800 [12738736.001]
  • [Cites] Carcinogenesis. 2003 Jul;24(7):1191-8 [12807722.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3638-46 [14512395.001]
  • [Cites] Bioinformatics. 2003 Dec 12;19(18):2448-55 [14668230.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2898-903 [15087409.001]
  • [Cites] J Cell Biochem. 2004 Jul 1;92(4):679-90 [15211566.001]
  • [Cites] Ann Surg. 2004 Oct;240(4):667-74; discussion 675-6 [15383794.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] Biochem J. 1997 May 15;324 ( Pt 1):311-9 [9164872.001]
  • [Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]
  • [Cites] Genomics. 1998 Mar 15;48(3):377-80 [9545645.001]
  • [Cites] J Mol Diagn. 2006 Sep;8(4):490-8; quiz 528 [16931590.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5043-51 [17075124.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:12-7 [17091451.001]
  • [Cites] Endokrynol Pol. 2006;57 Suppl A:18-25 [17091452.001]
  • [Cites] Int Immunopharmacol. 2006 Dec 20;6(13-14):1935-42 [17161346.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4193-8 [9751634.001]
  • (PMID = 18519760.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247-05; United States / NCI NIH HHS / CA / CA107247-01A1; United States / NCI NIH HHS / CA / R01 CA107247; United States / NCI NIH HHS / CA / R01-CA107247-01A1; United States / NCI NIH HHS / CA / CA107247-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS282977; NLM/ PMC3086681
  •  go-up   go-down



47. Bellezza I, Neuwirt H, Nemes C, Cavarretta IT, Puhr M, Steiner H, Minelli A, Bartsch G, Offner F, Hobisch A, Doppler W, Culig Z: Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol; 2006 Dec;169(6):2199-208
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To better understand the mechanisms of STAT3 regulation in benign and malignant prostate, we have investigated the role of suppressor of cytokine signaling (SOCS)-3.
  • SOCS-3 immunohistochemistry revealed a negative or weak reaction in benign areas, whereas its expression was detected in tumor tissue.
  • [MeSH-minor] Apoptosis. Cell Line, Tumor. Cell Proliferation. Humans. Interleukin-3 / metabolism. Janus Kinases / metabolism. Male. Methylation. RNA, Small Interfering. STAT3 Transcription Factor / metabolism. Suppressor of Cytokine Signaling 3 Protein. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Mar 19;274(12):7777-83 [10075669.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14133-8 [14617776.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10749-58 [15653674.001]
  • [Cites] Oncogene. 2005 Mar 17;24(12):2114-20 [15688010.001]
  • [Cites] Prostate. 2000 Jan;42(1):1-7 [10579793.001]
  • [Cites] Prostate. 2000 Feb 1;42(2):88-98 [10617865.001]
  • [Cites] Prostate. 2000 Feb 15;42(3):186-95 [10639189.001]
  • [Cites] J Pathol. 2000 Jul;191(3):239-44 [10878544.001]
  • [Cites] Leukemia. 2005 Feb;19(2):209-13 [15618960.001]
  • [Cites] Int J Hematol. 2003 Aug;78(2):106-13 [12953803.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):11-20 [14749471.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4774-82 [15256446.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1449-60 [15509516.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Mol Endocrinol. 1992 Jan;6(1):15-25 [1738367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3556-60 [1373503.001]
  • [Cites] Urology. 1995 Mar;45(3):542-9 [7879350.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4640-5 [9788616.001]
  • [Cites] Clin Cancer Res. 1996 Feb;2(2):379-87 [9816181.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):213-8 [9892209.001]
  • [Cites] Pediatr Nephrol. 2005 May;20(5):567-75 [15723195.001]
  • [Cites] Prostate. 2001 Jun 15;48(1):47-53 [11391686.001]
  • [Cites] Nat Med. 2005 Aug;11(8):892-8 [16007096.001]
  • [Cites] Int J Cancer. 2005 Nov 20;117(4):551-60 [15929083.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6406-17 [16007195.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6699-708 [16007169.001]
  • [Cites] Eur J Cancer. 2005 Nov;41(16):2502-12 [16199153.001]
  • [Cites] Endocrinology. 2006 Aug;147(8):3809-17 [16709613.001]
  • [Cites] Prostate. 2005 Jul 1;64(2):209-16 [15712220.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):38-43 [11071852.001]
  • [Cites] Endocrinology. 2000 Oct;141(10):3749-63 [11014231.001]
  • [Cites] Prostate. 2001 Aug 1;48(3):188-99 [11494334.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2941-8 [11555613.001]
  • [Cites] Mol Endocrinol. 2001 Nov;15(11):1880-90 [11682619.001]
  • [Cites] Mol Cell Biol. 2001 Dec;21(24):8471-82 [11713282.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):2159-65 [11733366.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 11;290(1):249-55 [11779161.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):339-45 [11786427.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):241-6 [11987152.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5632-6 [12384515.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6659-66 [12438264.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):233-41 [12507906.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):655-63 [12547723.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):594-600 [12576423.001]
  • [Cites] Oncogene. 2003 Feb 27;22(8):1247-52 [12606952.001]
  • [Cites] Endocrinology. 2003 Apr;144(4):1631-43 [12639948.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):27287-92 [12719422.001]
  • [Cites] Br J Cancer. 2003 Aug 4;89(3):524-32 [12888825.001]
  • (PMID = 17148681.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-3; 0 / RNA, Small Interfering; 0 / SOCS3 protein, human; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / Suppressor of Cytokine Signaling 3 Protein; 0 / Suppressor of Cytokine Signaling Proteins; E0399OZS9N / Cyclic AMP; EC 2.7.10.2 / Janus Kinases
  • [Other-IDs] NLM/ PMC1762483
  •  go-up   go-down



48. Versa-Ostojić D, Stanković T, Stemberger-Papić S, Vrdoljak-Mozetic D, Manestar M, Krasević M: Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. Anal Quant Cytol Histol; 2008 Jun;30(3):160-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints.
  • OBJECTIVE: To determine the morphometric characteristics of nuclei and silver-stained nucleolar organizer regions (AgNORs) on cytologic imprints and their value in differential cytodiagnosis of benign, atypical proliferative (borderline) and malignant ovarian mucinous tumors.
  • STUDY DESIGN: Forty-six mucinous ovarian tumor imprints (16 benign, 15 borderline, 15 malignant), were analyzed.
  • The nuclear area in benign tumors was larger than that in borderline tumors; malignant tumors had the highest values.
  • The total AgNOR area, number and relative area increased from benign through malignant tumors, with statistically significant differences among all groups.
  • By AgNOR size distribution, small AgNORs discriminate malignant from borderline and benign tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18630841.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / nucleolar organizer region associated proteins
  •  go-up   go-down



49. Atallah S, Albert M, Larach S: Transanal minimally invasive surgery: a giant leap forward. Surg Endosc; 2010 Sep;24(9):2200-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the clinical application of this technique and present preliminary data that show TAMIS to be an effective tool for resection of both malignant and benign lesions of the rectum.
  • Patients with biopsy-proven malignant lesions were required to undergo endorectal ultrasound preoperatively to determine tumor stage.
  • To perform TAMIS, a single-incision laparoscopic surgery port (SILS Port, Covidien) is introduced into the anal canal by applying steady manual pressure.
  • The average distance from the anal verge was 9.3 cm and the mean tumor diameter confirmed by pathology measured 2.93 cm.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Neoplasm Staging. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Colorectal Dis. 2008 Oct;23(10):1013-6 [18607608.001]
  • [Cites] World J Surg. 2009 May;33(5):1015-9 [19116734.001]
  • [Cites] Dis Colon Rectum. 2002 May;45(5):601-4 [12004207.001]
  • [Cites] Dis Colon Rectum. 2009 Jun;52(6):1107-13 [19581854.001]
  • [Cites] Colorectal Dis. 2007 Jul;9(6):553-8 [17573752.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2009 Jul;23(7):1419-27 [19347400.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):445-9 [19565297.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Asian J Surg. 2006 Oct;29(4):227-32 [17098653.001]
  • [Cites] Gastrointest Endosc. 2009 Jul;70(1):193-4 [19559847.001]
  • [Cites] Leber Magen Darm. 1985 Nov;15(6):271-9 [4079630.001]
  • [Cites] J Gastrointest Surg. 2009 Sep;13(9):1733-40 [19412642.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1376-80 [14571741.001]
  • [Cites] Minerva Chir. 2009 Aug;64(4):355-64 [19648856.001]
  • [Cites] Surg Technol Int. 2009 Apr;18:19-25 [19579186.001]
  • [Cites] Urology. 2009 Oct;74(4):805-12 [19643465.001]
  • [Cites] Colorectal Dis. 2006 Nov;8(9):795-9 [17032328.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Int Semin Surg Oncol. 2006 May 04;3:13 [16674824.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Dec;10(6):372-8 [11147912.001]
  • [Cites] Colorectal Dis. 2007 Mar;9(3):229-34 [17298620.001]
  • [Cites] Ann Surg. 2009 May;249(5):776-82 [19387326.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Aug;19(4):495-9 [19630589.001]
  • [Cites] Surg Endosc. 2009 May;23(5):1138-41 [19263120.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 20174935.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down



50. Voss M, Trojan L, Steidler A, Weiss C, Grobholz R, Alken P, Michel MS: Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia. Anal Quant Cytol Histol; 2008 Aug;30(4):199-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum vascular endothelial growth factor C level in patients with prostate cancer and benign prostatic hyperplasia.
  • OBJECTIVE: To compare serum vascular endothelial growth factor C (VEGF-C) levels in patients with benign prostatic hyperplasia (BPH) and prostate cancer (PCa) and analyze VEGF-C levels in relation to clinicopathologic parameters.
  • There was no correlation of VEGF-C to tumor stage, grading or the preoperative prostate-specific antigen values.
  • CONCLUSION: We cannot recommend VEGF-C serum level as a marker for tumor growth in PCa.



51. Ulisse S, Baldini E, Toller M, Delcros JG, Guého A, Curcio F, De Antoni E, Giacomelli L, Ambesi-Impiombato FS, Bocchini S, D'Armiento M, Arlot-Bonnemains Y: Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues. Endocr Relat Cancer; 2007 Sep;14(3):827-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its expression was found, with respect to HTU5 cells, unchanged in cells derived from a benign thyroid follicular tumor (HTU42), and significantly reduced in cell lines derived from follicular (FTC-133), papillary (B-CPAP), and anaplastic thyroid carcinomas (CAL-62 and 8305C).

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene Expr Patterns. 2003 May;3(2):203-11 [12711550.001]
  • [Cites] Genomics. 2003 Feb;81(2):192-201 [12620397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5974-9 [12714683.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8102-16 [14603251.001]
  • [Cites] Nat Rev Mol Cell Biol. 2003 Nov;4(11):842-54 [14625535.001]
  • [Cites] Nat Med. 2004 Mar;10(3):262-7 [14981513.001]
  • [Cites] BMC Evol Biol. 2004 Jun 18;4:16 [15207008.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5118-22 [1655245.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9004-8 [8090760.001]
  • [Cites] Thyroid. 1997 Dec;7(6):817-21 [9459622.001]
  • [Cites] Chromosoma. 1998 Dec;107(6-7):491-7 [9914382.001]
  • [Cites] Cell Growth Differ. 1999 Mar;10(3):155-62 [10099829.001]
  • [Cites] Genomics. 1999 Jun 1;58(2):165-70 [10366448.001]
  • [Cites] Oncogene. 1999 Jul 8;18(27):4032-8 [10435627.001]
  • [Cites] Trends Cell Biol. 1999 Nov;9(11):454-9 [10511710.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):52175-82 [15469940.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1122-7 [15592510.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13415-23 [15687499.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1057-66 [16172207.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2318-26 [12727991.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Nov;139(1):78-83 [12547166.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):78-83 [12490766.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):71-7 [12490765.001]
  • [Cites] Bioessays. 2002 Oct;24(10):915-25 [12325124.001]
  • [Cites] Int J Cancer. 2006 Jul 15;119(2):275-82 [16477625.001]
  • [Cites] J Cell Biol. 2005 Sep 26;170(7):1047-55 [16172205.001]
  • [Cites] Eur J Cancer. 2006 Oct;42(15):2631-8 [16928445.001]
  • [Cites] Mol Biol Cell. 2000 Apr;11(4):1357-67 [10749935.001]
  • [Cites] Mech Dev. 2000 Oct;97(1-2):13-26 [11025203.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14352-7 [11121038.001]
  • [Cites] Mol Genet Metab. 2001 Feb;72(2):155-63 [11161841.001]
  • [Cites] Science. 2002 Jan 18;295(5554):455-6 [11799231.001]
  • [Cites] J Cell Biol. 2002 Feb 4;156(3):437-51 [11827981.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):653-64 [11847113.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Mar;56(3):341-50 [11940046.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):222-5 [12062169.001]
  • [Cites] Oncogene. 2002 Aug 15;21(36):5619-30 [12165861.001]
  • (PMID = 17914111.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Microtubule-Associated Proteins; 0 / Piperazines; 0 / TACC3 protein, human; 639089-54-6 / VX680; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  • [Other-IDs] NLM/ PMC2216418
  •  go-up   go-down



52. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down



53. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, Al-Ahmadie H, Alves V, Xiao SY, Anders RA, Hart JA: Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol; 2010 Aug;34(8):1147-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The distinction of hepatocellular carcinoma (HCC) from metastatic tumor in the liver often presents a diagnostic challenge that carries significant impact on prognostication and therapy.
  • Arg-1 represents a sensitive and specific marker of benign and malignant hepatocytes that may ultimately prove to be a useful diagnostic tool in routine surgical pathology practice.
  • [MeSH-major] Arginase / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / enzymology. Hepatocytes / enzymology. Immunohistochemistry. Liver Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Clin Nutr Metab Care. 1998 Jul;1(4):335-9 [10565370.001]
  • [Cites] J Biomed Biotechnol. 2010;2010:683485 [20029630.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):689-94 [11345832.001]
  • [Cites] Am J Surg Pathol. 2002 Aug;26(8):978-88 [12170084.001]
  • [Cites] Hum Pathol. 2002 Dec;33(12):1175-81 [12514785.001]
  • [Cites] Mod Pathol. 2003 Feb;16(2):137-44 [12591966.001]
  • [Cites] Am J Clin Pathol. 2003 Mar;119(3):361-6 [12645337.001]
  • [Cites] J Immunol. 2004 Jun 15;172(12):7565-73 [15187136.001]
  • [Cites] Am J Clin Pathol. 2004 Jun;121(6):884-92 [15198362.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):514-20 [15221469.001]
  • [Cites] J Nutr. 2004 Oct;134(10 Suppl):2820S-2825S; discussion 2853S [15465793.001]
  • [Cites] Histochemistry. 1987;87(5):465-70 [3323144.001]
  • [Cites] Am J Pathol. 1993 Oct;143(4):1050-4 [7692729.001]
  • [Cites] Int J Dev Neurosci. 1994 Jun;12(4):337-42 [7976488.001]
  • [Cites] Mod Pathol. 1997 Jul;10(7):686-92 [9237179.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5347-54 [9605134.001]
  • [Cites] Mod Pathol. 1998 Oct;11(10):934-8 [9796718.001]
  • [Cites] Histopathology. 1998 Oct;33(4):318-24 [9822920.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2549-56 [15546957.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Acta Cytol. 2006 May-Jun;50(3):257-62 [16780018.001]
  • [Cites] Anal Quant Cytol Histol. 2006 Aug;28(4):181-7 [16927637.001]
  • [Cites] Virchows Arch. 2006 Sep;449(3):308-14 [16896894.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1570-5 [17122513.001]
  • [Cites] Arch Pathol Lab Med. 2007 Nov;131(11):1648-54 [17979482.001]
  • [Cites] Lab Invest. 2008 Jan;88(1):78-88 [18026163.001]
  • [Cites] Toxicology. 2008 Mar 20;245(3):194-205 [18291570.001]
  • [Cites] Am J Clin Pathol. 2008 Aug;130(2):224-30 [18628091.001]
  • [Cites] Arch Pathol Lab Med. 2008 Nov;132(11):1723-8 [18976006.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Dec 12;377(2):337-40 [18831962.001]
  • [Cites] BMC Dev Biol. 2008;8:107 [19000307.001]
  • [Cites] Int J Oncol. 2009 Mar;34(3):649-56 [19212669.001]
  • [Cites] PLoS Pathog. 2009 Apr;5(4):e1000371 [19360123.001]
  • [Cites] Acta Biochim Pol. 2009;56(3):465-9 [19636440.001]
  • [Cites] J Pathol. 2009 Nov;219(3):365-72 [19718708.001]
  • [Cites] Nitric Oxide. 2009 Nov-Dec;21(3-4):175-83 [19638312.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):874-81 [10955454.001]
  • (PMID = 20661013.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK081417; United States / NIDDK NIH HHS / DK / R01 DK081417-01; United States / NIDDK NIH HHS / DK / R01 DK081417-02
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.5.3.1 / Arginase
  • [Other-IDs] NLM/ NIHMS316258; NLM/ PMC3160135
  •  go-up   go-down



54. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tubulovillous adenoma of anal canal: a case report.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Examination revealed a 4 cm friable mass attached to the anus by a stalk.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • We believe the tubulovillus adenoma arose from either an anal gland or its duct that opens into the anus.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down



55. Ramirez JM, Aguilella V, Gracia JA, Ortego J, Escudero P, Valencia J, Esco R, Martinez M: Local full-thickness excision as first line treatment for sessile rectal adenomas: long-term results. Ann Surg; 2009 Feb;249(2):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selection criteria were benign sessile adenomas below the peritoneal reflection.
  • In the study period, 173 patients were operated on for an apparently benign rectal adenoma.
  • The mean distance of lower tumor was 7.6 cm (range, 1-18 cm), and the mean distance to upper edge was 11 cm (2-20 cm).
  • No statistical differences were found when comparing the histologic findings by tumor size, distance to the anal verge, or location.In 10 (5.8%) cases, the dissection was considered uncompleted because of a normal mucosa margin smaller than 1 mm.
  • CONCLUSIONS: In conclusion, a significant number of adenomas that we assumed preoperatively to be benign were already carcinomas and we were unable to find any reliable predictor to identify them.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Proctoscopy. Risk Factors. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212174.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down



56. Chen SP, Wang XP: Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation. Chin J Integr Med; 2006 Sep;12(3):221-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of Simotang oral liquid on anal exhaust in patients after abdominal gynecological operation.
  • OBJECTIVE: To study the effect of Simotang oral liquid and glycerin enema on the patients' bowel sound (BS) restoration and anal exhaust after abdominal gynecological operation.
  • METHOD: Ninety patients with benign tumor who had undergone gynecological operation were randomly divided into the Simotang group, treated after operation with Simotang oral liquid; the enema group, treated with glycerin enema, and the control group, non-treated.
  • The restoration time of BS and anal exhaust were observed.
  • RESULTS: Compared with the control group, the restoration time of BS and anus exhaust were both significantly shorter in the Simotang group and the enema group, showing statistical significance (P < 0.05); but the difference between the two treated groups was insignificant (P > 0.05).
  • CONCLUSION: Simotang oral liquid and glycerine enema both could benefit the restoration of anal exhaust and BS after abdominal operation.

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Constipation.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. GLYCERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17005087.001).
  • [ISSN] 1672-0415
  • [Journal-full-title] Chinese journal of integrative medicine
  • [ISO-abbreviation] Chin J Integr Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; PDC6A3C0OX / Glycerol
  •  go-up   go-down



57. Wibom C, Mörén L, Aarhus M, Knappskog PM, Lund-Johansen M, Antti H, Bergenheim AT: Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype. J Neurooncol; 2009 Sep;94(3):321-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic profiles differ between bone invasive and noninvasive benign meningiomas of fibrous and meningothelial subtype.
  • However, some tumors may, despite their benign appearance, display invasive growth behavior.
  • Tumor tissue from 13 patients with fibrous (6 invasive and 7 noninvasive) and 29 with meningothelial (10 invasive and 19 noninvasive) grade I meningiomas were analyzed by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI).
  • By analyzing the protein spectra in benign meningiomas we could differentiate between invasive and noninvasive growth behavior in both fibrous and meningothelial meningiomas of grade I.
  • [MeSH-major] Bone Neoplasms / metabolism. Bone Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Invasiveness / pathology. Proteomics

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Proteome Res. 2005 May-Jun;4(3):698-708 [15952716.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10199-204 [17047085.001]
  • [Cites] Cancer Sci. 2007 Feb;98(2):201-13 [17233837.001]
  • [Cites] Neurosurgery. 2008 Jan;62(1):53-8; discussion 58-60 [18300891.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2113-20 [17428078.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):343-5 [17471020.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):325-31 [15264244.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Apr 5;292(3):587-92 [11922607.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2319-24 [15330178.001]
  • [Cites] J Neurosurg. 2007 Nov;107(5):905-12 [17977259.001]
  • [Cites] Acta Neurol Scand. 1993 Mar;87(3):243-7 [8475698.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:139-46 [16515582.001]
  • [Cites] Prog Neurol Surg. 2007;20:142-9 [17317982.001]
  • [Cites] J Urol. 2005 Jan;173(1):73-8 [15592032.001]
  • [Cites] Anal Chem. 2008 Jan 1;80(1):115-22 [18027910.001]
  • [Cites] Electrophoresis. 2000 Apr;21(6):1164-77 [10786889.001]
  • [Cites] Strahlenther Onkol. 2006 Nov;182(11):635-40 [17072520.001]
  • [Cites] Surg Neurol. 1997 Nov;48(5):501-6 [9352816.001]
  • [Cites] Neurosurgery. 2007 Dec;61(6):1194-8; discussion 1198 [18162898.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):60-4 [16871881.001]
  • [Cites] Cancer Biol Ther. 2007 Mar;6(3):391-6 [17264672.001]
  • [Cites] Neuropathology. 2007 Oct;27(5):407-12 [18018472.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1853-63 [16736004.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):461-6 [6310067.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:44-8 [11386825.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E3 [17961040.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):247-53 [16229881.001]
  • [Cites] Clin Chem. 2006 Nov;52(11):2103-6 [16990423.001]
  • [Cites] Clin Chem. 2005 Jan;51(1):102-12 [15613711.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1002-14 [18281532.001]
  • [Cites] Stereotact Funct Neurosurg. 2005;83(1):45-51 [15860936.001]
  • (PMID = 19350207.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down



58. Nattkemper TW, Wismüller A: Tumor feature visualization with unsupervised learning. Med Image Anal; 2005 Aug;9(4):344-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor feature visualization with unsupervised learning.
  • Dynamic contrast enhanced magnetic resonance imaging (DCE MRI) is applied for diagnosis and therapy control of breast cancer.
  • Computer-based diagnosis (CAD) systems have been proposed to analyze and classify signal time curve data, extracted from hand selected ROI in the DCE MRI data.
  • In this paper, we apply the self-organizing map (SOM) to a set of time curve feature vectors of single voxels from seven benign lesions and seven malignant tumors.
  • Using the trained SOM, we are able to identify voxels with benign or malignant signal characteristics and to visualize lesion cross-sections with pseudo-colors.
  • [MeSH-minor] Contrast Media. Diagnosis, Computer-Assisted. Female. Gadolinium DTPA. Humans



59. Cho SD, Herzig DO, Douthit MA, Deveney KE: Treatment strategies and outcomes for rectal villous adenoma from a single-center experience. Arch Surg; 2008 Sep;143(9):866-70; discussion 871-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective review of patient and tumor characteristics, procedure, recurrence, and complications.
  • Mean tumor size was 3.0 cm (range, 0.5-11 cm) and the mean distance of the tumor from the anal verge was 4.9 cm (range, 0-10 cm).
  • Tumor size did not correlate with malignancy.
  • There were 4 (12.5%) benign recurrences, all after transanal excisions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794424.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down



60. Zhang S, Gao F, Chen LS, Tang ZJ, Liang JL, Wu Q: [Clinical analysis of anorectal malignant melanoma]. Zhonghua Wei Chang Wai Ke Za Zhi; 2005 Jul;8(4):309-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The onset of symptom was hematochezia, then anus prolapses.
  • 94.7% of patients had AMM within 5 cm from anus margin; the average tumor size was (3.3+/- 2.1) cm.
  • More than a half (54.5%) of the tumor was movable, 19.1% smooth surfaced, 6.6% soft textured.
  • Half of the patients were misdiagnosed,and over 50% of patients were misdiagnosed as benign disease.
  • Mile's operation was performed in most of patients (63%), while anal resection was performed in 30% of the patients.
  • [MeSH-major] Anus Neoplasms / pathology. Melanoma / pathology. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167248.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down



61. Skvortsova TE, Rykova EY, Tamkovich SN, Bryzgunova OE, Starikov AV, Kuznetsova NP, Vlassov VV, Laktionov PP: Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation. Br J Cancer; 2006 May 22;94(10):1492-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell-free and cell-bound circulating DNA in breast tumours: DNA quantification and analysis of tumour-related gene methylation.
  • Tumour development is characterised by the increased circulating DNA (cirDNA) concentration and by tumour-related changes in blood plasma DNA.
  • Tumour development was shown to lead to significant changes in the distribution of cirDNA between cell-free and cell-surface-bound fractions.
  • Analysis of RARbeta2 and RASSF1A methylation in the total cirDNA provides 95% diagnostic coverage in breast cancer patients, 60% in patients with benign lesions, and is without false-positive results in healthy women.
  • Results of the study indicate that methylation-specific PCR of RARbeta2 and RASSF1A genes based on the total cirDNA combined with the quantitative analysis of cirDNA distribution between cell-bound and cell-free fractions in blood provide the sensitive and accurate detection and discrimination of malignant and benign breast tumours.
  • [MeSH-major] Breast Neoplasms / blood. DNA Methylation. DNA, Neoplasm / blood. DNA-Binding Proteins / genetics. Fibroadenoma / blood. Receptors, Retinoic Acid / genetics. Transcription Factors / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann N Y Acad Sci. 2000 Apr;906:5-7 [10818586.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:191-6 [17108211.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Ann Surg Oncol. 2002 Jan-Feb;9(1):71-6 [11829433.001]
  • [Cites] Anticancer Drugs. 2002 Apr;13(4):353-7 [11984080.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5462-82 [12154408.001]
  • [Cites] Int J Cancer. 2003 Jan 10;103(2):149-52 [12455027.001]
  • [Cites] Nature. 2004 May 27;429(6990):457-63 [15164071.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:217-20 [15251963.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1022:221-7 [15251964.001]
  • [Cites] Anal Biochem. 1980 Mar 1;102(2):344-52 [6158890.001]
  • [Cites] J Clin Invest. 1985 Dec;76(6):2182-90 [3001145.001]
  • [Cites] Mol Biol (Mosk). 1988 Nov-Dec;22(6):1667-72 [3252155.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2315-24 [10325420.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3956-63 [10339505.001]
  • [Cites] Histol Histopathol. 1999 Oct;14(4):1159-64 [10506932.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):873-7 [15560075.001]
  • [Cites] Int J Cancer. 2000 Jul 20;89(4):389-94 [10956415.001]
  • (PMID = 16641902.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / HIC1 protein, human; 0 / Kruppel-Like Transcription Factors; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  • [Other-IDs] NLM/ PMC2361269
  •  go-up   go-down



62. Nordgård O, Oltedal S, Kørner H, Aasprong OG, Tjensvoll K, Gilje B, Heikkilä R: The potential of cytokeratin 20 and mucin 2 mRNA as metastasis markers in regional lymph nodes of colon cancer patients investigated by quantitative RT-PCR. Int J Colorectal Dis; 2009 Mar;24(3):261-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Both assays were able to detect dilutions of tumor cells down to one tumor cell in 10(6) normal lymphocytes.
  • CK20 and MUC2 mRNA were quantitated in 52 normal lymph nodes from 12 patients undergoing surgery for benign bowel diseases and in 144 primary colon tumors.
  • The median tumor level of both markers were more than 10(4)-fold higher than the highest level in normal lymph nodes, indicating that the markers had a potential for metastasis detection in a clinical context.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Keratin-20 / genetics. Lymph Nodes / pathology. Mucin-2 / genetics. Reverse Transcriptase Polymerase Chain Reaction
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Lymphocytes / metabolism. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anal Biochem. 2006 Sep 15;356(2):182-93 [16899212.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1070-80 [17206482.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] Int J Colorectal Dis. 2004 Mar;19(2):87-94 [13680284.001]
  • [Cites] World J Surg. 2007 Jun;31(6):1304-12 [17460811.001]
  • [Cites] Cancer Detect Prev. 2000;24(1):72-9 [10757125.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):412-7 [14648708.001]
  • [Cites] Ann Surg Oncol. 2006 Nov;13(11):1386-92 [17009147.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1049-55 [11844829.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):101-10 [15185350.001]
  • [Cites] Nat Biotechnol. 2001 Nov;19(11):1011-2 [11689839.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):520-3 [16510433.001]
  • [Cites] Int J Cancer. 2003 Nov 20;107(4):617-28 [14520701.001]
  • [Cites] Br J Cancer. 2006 Jul 17;95(2):218-25 [16755296.001]
  • [Cites] J Mol Diagn. 2007 Nov;9(5):563-71 [17916603.001]
  • (PMID = 19119477.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Mucin-2; 0 / RNA, Messenger
  •  go-up   go-down



63. Liu J, Lau SK, Varma VA, Kairdolf BA, Nie S: Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots. Anal Chem; 2010 Jul 15;82(14):6237-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiplexed detection and characterization of rare tumor cells in Hodgkin's lymphoma with multicolor quantum dots.
  • Here, we report the use of multiplexed QDs and wavelength-resolved imaging to detect and characterize a class of low-abundant tumor cells in Hodgkin's lymphoma.
  • Known as the Hodgkin's and Reed-Sternberg (HRS) cells, this class of malignant cells is a pathological hallmark in clinical diagnosis, but it comprises only about 1% of the heterogeneous infiltrating cells in lymph node tissues.
  • The results indicate that a distinct QD staining pattern (CD15 positive, CD30 positive, CD45 negative, and Pax5 positive) can be used to not only detect Hodgkin's lymphoma but also differentiate it from benign lymphoid hyperplasia.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • [Cites] ACS Nano. 2010 May 25;4(5):2755-65 [20377268.001]
  • [Cites] J Clin Pathol. 2002 Mar;55(3):162-76 [11896065.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1160-9 [12142368.001]
  • [Cites] Cancer Detect Prev. 2002;26(4):249-55 [12430629.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117 Suppl:S76-94 [14569804.001]
  • [Cites] Nat Biotechnol. 2004 Jan;22(1):47-52 [14704706.001]
  • [Cites] J Clin Pathol. 1987 Nov;40(11):1298-304 [3320093.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2905-17 [8639911.001]
  • [Cites] J Pathol. 1997 Apr;181(4):462-3 [9196447.001]
  • [Cites] Mol Med Today. 1995 Apr;1(1):26-30 [9415134.001]
  • [Cites] Science. 2005 Jan 28;307(5709):538-44 [15681376.001]
  • [Cites] Curr Opin Biotechnol. 2005 Feb;16(1):63-72 [15722017.001]
  • [Cites] J Biomed Opt. 2005 Jul-Aug;10(4):41207 [16178631.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1853-61 [16385563.001]
  • [Cites] Expert Rev Mol Diagn. 2006 Mar;6(2):231-44 [16512782.001]
  • [Cites] Mod Pathol. 2006 Sep;19(9):1181-91 [16778828.001]
  • [Cites] Nano Lett. 2006 Dec;6(12):2881-6 [17163724.001]
  • [Cites] Nat Protoc. 2007;2(5):1152-65 [17546006.001]
  • [Cites] Mod Pathol. 2007 Aug;20(8):871-7 [17529924.001]
  • [Cites] Annu Rev Biomed Eng. 2007;9:257-88 [17439359.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1226-40 [18495291.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Sep 19;374(2):181-6 [18621021.001]
  • [Cites] J Pathol. 2008 Nov;216(3):275-85 [18814189.001]
  • [Cites] Nat Rev Cancer. 2009 Jan;9(1):15-27 [19078975.001]
  • [Cites] Nat Methods. 2009 Feb;6(2):139-41 [19137005.001]
  • [Cites] Biomaterials. 2009 May;30(15):2912-8 [19251316.001]
  • [Cites] Annu Rev Pathol. 2009;4:151-74 [19400691.001]
  • [Cites] Trends Biotechnol. 2009 Jun;27(6):350-8 [19409634.001]
  • [Cites] Biosens Bioelectron. 2009 Aug 15;24(12):3657-62 [19540102.001]
  • [Cites] J Mol Histol. 2009 Aug;40(4):261-8 [19908148.001]
  • [Cites] ACS Nano. 2010 Jan 26;4(1):488-94 [20041634.001]
  • [Cites] N Engl J Med. 2010 Mar 11;362(10):875-85 [20220182.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • (PMID = 20565106.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA108468; United States / NCI NIH HHS / CA / CA119338-01; United States / NCI NIH HHS / CA / U54CA119338; United States / NCI NIH HHS / CA / U54 CA119338; United States / NCI NIH HHS / CA / CA108468-01; United States / NCI NIH HHS / CA / R01 CA108468-01; United States / NCI NIH HHS / CA / R01CA108468; United States / NCI NIH HHS / CA / U54 CA119338-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers
  • [Other-IDs] NLM/ NIHMS220487; NLM/ PMC2914471
  •  go-up   go-down



64. Bearzi I, Mandolesi A, Arduini F, Costagliola A, Ranaldi R: Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors. Anal Quant Cytol Histol; 2006 Jun;28(3):137-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor. A study of 158 cases: clinicopathological features and prognostic factors.
  • RESULTS: Most of the GISTs had a benign behavior.
  • CONCLUSION: Mitotic activity is important in predicting the outcome of patients with high risk GIST who present at diagnosis without dissemination.

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786723.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Protei